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Abstract 
Introduction: The acute and chronic adverse physiological consequences of anticancer therapy 
include direct injury to the entire cardiovascular-skeletal muscle axis. As such, these patients are 
at an increased risk of both cancer therapy-related and age-related pathological outcomes; 
primary cardiovascular disease, exercise intolerance, and cancer-related fatigue. To date, 
however, therapeutic strategies that mitigate these negative effects within the human body have 
yet to be established. Previous work has demonstrated that dietary nitrate (NO3
-) 
supplementation can improve cardiac, vascular and cardiorespiratory exercise parameters, 
highlighting its potential therapeutic use in clinical populations. Therefore, we hypothesized that 
NO3
- supplementation would improve both cardiac performance and exercise capacity.   
Methods: To date, 6 cancer survivors (57 ± 11 years) with a history of anticancer therapy 
completed a randomized, double-blind, crossover study with a single, acute-dose administration 
of NO3
- or placebo (PL) [140 ml]. Transthoracic echocardiographic measures at rest were made 
to obtain left ventricular stroke volume. Patients performed a supine-cycling steady-state 
exercise test (30W) with measurements of arterial blood pressure, stroke volume, cardiac output, 
and a maximal-effort cardiopulmonary exercise test.  
Results: As intended, there was a statistically significant increase in plasma nitrite during the 
NO3
- condition compared to PL (NO3
- 1300 ± 963 µM vs. PL 111 ± 49 µM, respectively; P = 
0.02). Additionally, we observed a decrease in relative oxygen uptake (VO2) during steady-state 
exercise with NO3
- compared to PL (NO3
- 8.46 ± 2.2 vs. PL 8.98 ± 2.4 ml/kg/min; p = 0.01; 
Absolute VO2: BRJ 0.64 ± 0.10 vs. PL: 0.68 ± 0.11 L/min; p = 0.01) indicating an improved 
exercise efficiency. Resting and steady-state arterial blood pressure, stroke volume, and cardiac 
output were not different between conditions. Furthermore, we did not observe any differences 
  
between conditions for peak relative VO2 (NO3
- 22.42 ± 3.86 vs. PL 23.14 ± 4.01 ml/kg/min; p = 
0.23), total work done (NO3
- 70.64 ± 29.5 vs PL 70.67 ± 30.71 kJ; p = 0.49), or for gross 
exercise efficiency (NO3
- 5.23 ± 1.48 vs. PL 4.97 ± 1.41 kJ/L O2; p = 0.14) during the maximal-
effort cardiopulmonary exercise test. 
Conclusions: A single, acute-dose of inorganic nitrate supplementation in cancer survivors with 
a history of anticancer therapy enhanced steady-state exercise efficiency, but had no effect on 
exercise cardiac performance or peak exercise capacity.  
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Chapter 1 - Annotated Bibliography 
Selected articles that are critically related to the development of this thesis.  
 
Effect of Inorganic Nitrate on Exercise Capacity in Heart Failure With Preserved Ejection 
Fraction. Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, Doulias PT, 
Ischiropoulos H, Townsend RR, Margulies KB, Cappola TP, Poole DC, and Chirinos JA. 
Circulation 131: 371-380; discussion 380, 2015. 
 
Purpose: This study tested the hypothesis that: administering inorganic nitrate supplementation 
would improve exercise capacity in HFpEF individuals. They also investigated the effect of 
inorganic nitrate on the vasculature and skeletal muscle to obtain insight into the mechanisms 
through which an effect on exercise tolerance may occur. Methods: Inclusion criteria included 
those (human subjects) who have symptomatic heart failure with a preserved ejection fraction 
(>50%) with a ratio of early mitral inflow velocity to septal tissue velocity and one other sign of 
chronically elevated filling pressures. Study was a randomized, double-blind, crossover study with 
single dose of inorganic nitrate from concentrated beet root juice containing 12.9 mmol NO3- in 
140 ml versus placebo control. Washout was at least 5 days (range: 5-42 days). Exercise efficiency 
was measured (ratio of total work performed to total oxygen consumed) along with measurements 
of peak VO2, vasodilatory reserve during exercise (change in peripheral vascular resistance from 
rest to peak exercise), and skeletal muscle mitochondrial oxidative function. Arterial wave 
reflections were also assessed during post occlusion of the forearm. Patients performed a maximal 
exertion-limited exercise test using a graded exercise protocol on a cycle ergometer. Resistance 
started at 12.5 W for 3 minutes and then increased to 25 W for 3 minutes and then increasing every 
3 minutes by 25 W. 15 minutes after this exercise is when patients underwent a 6 minutes 25 W 
constant resistance load. Post occlusion hyperemia test was performed to determine mVO2 
recovery.  Results: This study found that peak VO2, total work performed, and exercise duration 
were all significantly increased after NO3- supplementation. Ventilatory threshold was 
significantly greater after NO3- supplementation and also enhanced the reduction in SVR at peak 
exercise and also a significant increase in cardiac output versus placebo control. The same for an 
increase in stroke volume and heart rate. Steady state VO2 was not different between treatments. 
No difference in mVO2 between arms of placebo control and BRJ during rest but during exercise 
mVO2 recovery back to baseline tended to be shorter with BRJ. Brachial flow after cuff release 
was greater in BRJ arm. Discussion: A single dose of BRJ before exercise significantly improves 
peak VO2 in subjects with HFpEF. This was accompanied by a reduction in SVR, increase in 
cardiac output, and increase in VO2 at which ventilatory threshold occurred. Suggestive that NO3- 
improves exercise capacity in HFpEF by improving peripheral response to exercise and by 
providing greater O2 delivery to exercising muscles. Improvements in oxidative function have also 
been demonstrated in this study with the use of NIRS after NO3- supplementation which is 
suggestive of improved ATP production.   
  
  
Dietary nitrate supplementation reduces the O2 cost of walking and running: a placebo-
controlled study  
Lansley, Katherine; Winyard, Paul; Fulford, Jonathan; Vanhatalo, Anni; Bailey, Stephen; 
Blackwell, Jamie; DeMenna, Fred; Gilchrist, Mark; Benjamin, Nigel; and Jones, Andrew.  
2 
Journal of applied physiology 110: 591-600; discussion, 2011. 
 
Purpose: 1) To determine whether physiological effects of BR supplementation were consequent 
to the high NO3- content of BR 2) Investigate the extent to which elevation of NO bioavailability 
through BR consumption might increase mitochondrial biogenesis and thus contribute to reported 
improvements in aerobic exercise performance 3) To extend previous findings from own lab in 
knee-extension and cycling  to walking and running to broaden intervention application  It was 
hypothesized that: 1) Relative to placebo, BR would increase plasma NO2- and reduce Blood 
Pressure. 2) Also, BR would reduce O2 cost of walking and running and increase exercise 
tolerance measured as time to task failure. 3) BR would increase muscle oxidative capacity as 
assed by Q max 4) NO3- depleted placebo would not alter physiological indexes relative to pre-
intervention control indicating physiological effects (4-6 days) of BR are related to NO3- 
content.  Methods: Randomized, double blind, crossover study with 9 male subjects (aged 22+- 4 
years) all healthy with supplementation of either BR or placebo for 6 days with a 10 day washout 
period. BR supplement was 0.5 l/day containing 6.2 mmol of NO3- and placebo was 0.5 l/day of 
0.0034 mmol of NO3- which was NO3- depleted BR. Incremental ramp performed prior to 
supplementation to determine VO2 max and GET. Day 4 and 5 were used for testing in which day 
4 was two 6 min bouts of moderate (80% GET) and 1 exhaustive bout of severe intensity running 
(75% delta) Day 5 was two 6 min bouts of moderate (80% GET) and one 6 min bout of 
severe (75% delta). Day 6 of testing, subjects were required to complete an incremental, single-
legged, knee-extension exercise test consisting of a 42 second bout at 81.2% +- 4.3% of individual 
max.  Results: BR significantly reduced systolic BP compared to placebo. Baseline walking 
VO2 reduced by 12% compared to placebo. And absolute VO2 during last 30 sec of 
running moderately was significantly lower following BR supplementation. VO2 reduced by BR 
by 14% during walking compared to placebo and VO2 was reduced by 6% at task failure compared 
to placebo. All subjects had higher exercise tolerance as shown from increased time to task failure 
of 15% and all 9 subjects were able to exercise longer compared to placebo.  Conclusion: 1) Short-
term (4-6 days) dietary BR increased plasma NO3- and reduced systolic BP 2) BR reduced the O2 
cost of walking and moderate and severe intensity running 3) increased the time to task failure 
during constant-speed severe intensity running and incremental knee-extension exercise. BR 
intake resulted in 12% reduction of O2 cost of walking. Steady state VO2 during moderate 
intensity running was reduced by 7%. Results seen within 4 days of supplementation. Findings are 
related to NO2- and NO mediated effects on muscle contractile function rather than changes in 
mitochondrial volume.   
  
A comparison of organic and inorganic nitrates/nitrites   
Omar, Sami; Artime, Esther; and Webb, Andrew.  
Nitric Oxide 229-40. 2012.  
 
Purpose: Review will compare similarities and differences between organic nitrate/nitrites and 
inorganic nitrates/nitrites in chemical structures, bio-activation pathways, pharmacological 
activity and effects. As well as future therapeutic applications for inorganic nitrate/nitrite.   
Methods: Review covered both human and animal applications in terms of the use of organic 
nitrate/nitrite used for clinical applications for treatment of CVD. Organic nitrate/nitrites in the 
blood stream levels will quickly rise and have rapid onset of action (1-3 mins) but it is also clearly 
rapidly from the blood which gives a rapid offset (15-30 min). Chronic use may lead to endothelial 
dysfunction due to vascular tolerance thus triggering ROS and aggravating the tolerance.  
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However, inorganic nitrate/nitrite is added to cure meats as a preservative but after ingestion, can 
be produced in mammalian tissue by the oxidation of the NO produced from the enzymatic 
degradation of L-arginine. Reduction to nitrite is largely via entero-salivary circulation. Nitrate 
levels rise within 30 mins and a peak of 3 hours and is sustained for up to 24 hours. Nitrite rise is 
more gradual by 1-1.5 hours and then a plateau around 2.5 hours and remain elevated for 6 hours. 
If inorganic nitrate is ingested orally, its bioavailability is 95-98%. Nitrate-nitrite-NO pathway is 
enhanced by hypoxic and acidic conditions. The World Cancer Research Fund/American Institute 
of Cancer Research found no evidence linking ingestion of vegetables high in nitrate with 
development of cancer. Dietary Approach to Stop Hypertension (DASH) found dietary intake of 
fruits and vegetables for three weeks resulted in a reduction in both systolic and diastolic BP. 
Inorganic nitrate/nitrite consumption offers cytoprotection against I/R injury, inhibition of platelet 
aggregation, BP reduction, and reduction in the O2 cost during exercise. Endothelial function 
= eNOS to generate NO and EDRF. Results: Organic nitrates may be effective in lowering BP and 
used acutely for hypertensive emergencies, the effect is variable and longer-term use is limited by 
the rapid development of tolerance. A study in rats found continuous delivery of organic nitrate 
lead to an increase in infarct area however, on the other hand, a discontinuation of treatment 3 hour 
prior to ischaemic event caused a decrease in infarct size.   
Inorganic nitrate/nitrite was found to decrease infarct size and restored cardiac function in in vitro 
and in in vivos models. Summary: In contrast to organic nitrates, inorganic nitrites now hold 
considerable promise as a treatment for myocardial infarction and is currently being used in clinical 
trials.   
  
Dietary nitrate provides sustained blood pressure lowering in hypertensive patients. A 
randomized, phase 2, double-blind, placebo-controlled study   
Kapil, Vikas; Khambata, Rayomand; Robertson, Amy; Caulfield, Mark; and Ahluwalia Amrita. 
Hypertension 320-7. 2014.  
 
Purpose: To explore whether once daily dietary nitrate supplementation for 4 weeks would confer 
sustained BP reduction in both drug-naïve and treated patients with hypertension   
Methods: 68 patients entered in a double-blind, randomized, placebo-controlled trial. Aged 18-85 
years old and uncontrolled BP monitoring of >130/85 mmHg. 34 patients received a placebo of 4 
weeks daily of 250 mL nitrate-depleted BRJ with 0.007 mmol of nitrate daily and 34 patients 
received 250 mL daily for 4 weeks of BRJ with 6.4 mmol of nitrate daily. Patients recorded once 
daily home BP for two weeks and then a pre-intervention where ambulatory BP was taken. After 
this is when the patients were asked for consume their respective treatment for 4 wks and then 
there was a two week washout period and the patients were then asked to come back in for another 
ambulatory BP test. Findings: Dietary nitrate ingestion showed elevations in both nitrate and nitrite 
concentrations but this returned back to baseline after the 2 week washout period. Plasma nitrite 
levels were elevated from baseline by 2.7 fold with no change in the placebo limb of the 
study. Change in circulating nitrite and nitrate levels associated with 1.4 fold increase in plasma 
cGMP concentrations with no change in the placebo. Home BP was reduced within 1 week of 
dietary nitrate consumption and reduced over the entire 4 week intervention period. This did not 
hold true for the placebo group. Peak decreases in BP occurred at 6 weeks (last week of dietary 
supplementation. After washout, BP began returning to baseline. There were no changes relative 
to baseline or compared to placebo in HR. Pulse wave velocity was reduced after BRJ consumption 
compared with baseline. Conclusion: In treated hypertensive patients, PWV was reduced after 
4 
dietary nitrate and endothelial function was improved (change in FMD compared to placebo). 
Once daily nitrate intervention augments NO generation through pathway in patients with 
hypertension to lower BP. Nitrate administration over 4 weeks shows absence of lack of tolerance 
which is seen in organic nitrate supplementation.    
  
Mechanisms underlying blood pressure reduction by dietary inorganic nitrate   
Carlstrom, M; Lundberg, J.O.; and Weitzberg, C. 
Acta Physiologica. 2018. 
 
Purpose: Describe how dietary nitrate affects various organ systems and discuss underlying 
mechanisms that may contribute to the observed blood pressure lowering effects. Methods: Both 
rat and human models were discussed in this review.  Findings: Both normotensive and 
hypertensive humans showed a lowering of BP with nitrate supplementation. Activity of eNOS is 
regulated by intracellular calcium that activates calmodulin which binds to eNOS and increases 
enzyme activity. When BH4 is limited, eNOS uncoupling occurs and the enzyme generates 
superoxide anions instead of NO. Induction of iNOS leads to higher amounts of NO which 
contribute to the innate immune system by killing bacteria, viruses, and fungi. INOS is highly 
expressed in several inflammatory states including cancer and atherosclerosis but its role in the 
CVD inflammatory process is still unclear. A study wherein 500 mL of BRJ was administered to 
a group of healthy subjects BP was reduced and BRJ protected the vascular endothelium 
from ischaemic injury and caused a reduction in ex vivo platelet aggregation. Dietary nitrates have 
the ability to reduce BP in normotensive and provide sustained reduction in BP in hypertensive 
patients. Infusing nitrite in brachial artery of healthy subjects caused an increase in forearm blood 
flow. ANG 2 induced vasoconstriction was markedly attenuated in renal arterioles from mice with 
dietary nitrate pre-treatment for 1 week. Dietary nitrates reduced arterial stiffness and improved 
endothelial function. Nitrite is a positive modulator of the Frank-Starling respond in the rat 
heart. Rammos and colleagues showed that 8 weeks of nitrate supplementation to old mice 
improved LV diastolic function, arterial compliance, and coronary flow reserve that were coupled 
to accelerated cardiomyocyte calcium handling which was coupled to increase 
cGMP signaling. Numerous studies have found that oxidative stress and subsequent NO 
deficiency in the kidney are critically associated with development of hypertension an increased 
risk of adverse CV complications. Chronic supplementation with inorganic nitrate attenuated 
hypertension, renal and cardiac injuries in rats with compromised kidney function and high salt 
diet. In mice, dietary nitrate supplementation for 2 weeks increased renal blood flow and GFR and 
attenuated the decline in kidney function and renal injuries that developed 2 weeks following the 
ischaemic event.  Conclusion: Numerous pre-clinical trials and clinical studies demonstrate that 
inorganic nitrate supplementation is associated with favorable CV outcomes including reduced 
BP.   
  
Acute administration of inorganic nitrate reduced VO2 Peak in endurance athletes   
Bescos, Raul; Rodriguez, Ferran; Iglesias, Xavier; Ferrer, Miguel, Iborra, Elena; and Pons, Antoni  
Medicine and Science in Sports and Exercise 1979-86. 2011. 
 
Purpose: Aim was to assess the effect of a single dose of nitrate given before cycling to see the 
change in cardiorespiratory and metabolic response in endurance athletes at different intensities. 
It was hypothesized that nitrate supplementation would not be effective in improving the 
cardiorespiratory response to exercise at low to moderate intensities with highly athletic cyclists. 
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However, at higher intensities where acidosis and low O2 tension occur the nitrate-nitrite-NO 
pathway could be activated and increase tolerance to high intensity cycling which was measured 
as time to task failure.  Methods: 11 male cyclists were enrolled in a randomized, double-blind, 
crossover study to receive a single dose of either sodium nitrate (10mg/kg) or sodium chloride in 
250 ml of water with a 7-day washout period. Drinks were ingested 3 hours prior to exercise. First 
cycle ergometer test was submaximal at 2.0,2.5,3.0, and 3.5 W/kg with each load lasting 6 
mins with 3 mins of passive recovery. Five minutes after the submaximal workloads, 
subjects performed an incremental exercise test to volitional exhaustion starting at 3.0 W/kg and 
the WR increased by 0.5 W/kg every minute. Four blood samples were collected for nitrate and 
nitrite analysis as well as capillary blood samples for lactate analysis were 
collected.  Findings: After nitrate supplementation, the plasma levels were significantly lower 
after submaximal and maximal exercise compared to the peak value reached after 3 hours of 
supplementation. VO2 tended to be lower at the respiratory compensation point after nitrate 
supplementation than after the placebo. No difference in time to exhaustion compared between 
treatments.  Conclusion: After a single dose of nitrate supplementation, there was no change in 
cardiorespiratory adaptation at low to moderate intensities on cycle ergometer in highly trained 
cyclists. However, at maximal intensity there were significant differences between groups. VO2 
peak was significantly reduced without affecting the maximal attainable work, blood lactate, or 
other cardiorespiratory parameters. So, the second hypothesis was so confirmed as there was no 
significant difference in time to task failure between treatments.   
  
Effects of dietary nitrate on oxygen cost during exercise   
Larsen, F; Weitzberg, E; Lundberg, J; and Ekblom, B.  
Acta Physiologica 59-66. 2007.  
 
Purpose: If the administration of dietary nitrate would lead to increased systemic storage pools of 
nitrite and if this dietary strategy would have an impact on various physiological and biochemical 
parameters during exercise.  Methods: Double-blind, placebo-controlled, cross-over design with 9 
healthy, well trained males. Study consisted of a familiarization day as well as two 3-day periods 
separated by a 10 day washout period. Subjects started with either 0.1 mmol sodium nitrate/kg or 
equal amount of sodium chloride as the placebo. Testing was done on a cycle 
ergometer. Submaximal levels were adjusted to correspond to 45, 60, 70, 80, and 85% VO2 
peak.  Findings: Average resting BP was lowered in nitrate group compared with the placebo 
group. There was a pronounced decrease in nitrite concentrations during exercise which was more 
pronounced in nitrate group than in the control group. After nitrate administration, VO2 was 
significantly lower during the four work rates corresponding to 45-80% of VO2 peak compared 
with placebo. There were no differences in; HR, VE, VE/VO2, or RER during any of the 
submaximal work rates between groups. There was also no significant difference in VO2 peak 
between groups. Clear lowering of oxygen cost after nitrate diet at 45% VO2 peak.  Conclusion: A 
significantly reduced oxygen demand at the four lowest submaximal work rates was notes after 
nitrate administration. Showing that dietary supplementation with inorganic nitrate, in an 
achievable amount through a diet rich in vegetables, results in a reduced VO2 during submaximal 
work and a significant increase in muscular efficiency and energy production efficiency.   
  
Dietary nitrate reduces maximal oxygen consumption while maintaining work performance 
in maximal exercise   
6 
Larsen, Filip; Weitzberg, Eddie; Lundberg, Jon; and Ekblom, Bjorn.  
Free Radical Biology and Medicine 342-7. 2009.  
 
Purpose: Study the effect of nitrate supplementation on maximal combined arm and leg exercise. 
To investigate whether dietary nitrate would also influence VO2 max during exercise with large 
active muscle groups and if this would have any effect on the time to exhaustion during incremental 
exercise. Investigators also studied the effects of nitrate supplementation on plasma nitrite kinetics 
during exercise and BP in the acute recovery period after exhaustive exercise. Methods: 9 (7 male 
and 2 female) healthy subjects participated in a randomized double-blind cross-over study with 
two trials and at least a 7 day washout period. Maximal exercise tests were performed using two 
combined cycle ergometers with one used ordinarily and then the other used as an arm ergometer. 
Cadence was set to 80 rpm for both arms and legs and the exercise protocol was an incremental 
exercise to exhaustion. Nitrate supplementation was 0.033 mmol NaNO3/kg three times daily with 
the last dose taken 40 minutes before exercise test was administered. Placebo consisted of equal 
amount of NaCl.  Findings: After nitrate supplementation VO2 max was reduced. Heart rate and 
pulmonary ventilation were unaffected by nitrate supplementation. Time to exhaustion showed a 
near-significant increase after nitrate supplementation. One hour after a single dose of nitrate, VO2 
was decreased but was unchanged in the placebo trials. There was no significant change in blood 
pressure this may be due to the time of blood pressure as it was taken 40 minutes after ingestion, 
weak statistical power, and lower supplementation period. Conclusion: Nitrate supplementation 
decreases VO2 max at maximal combined arm and leg exercise but this trended to an increased 
performance as shown by the increased time to exhaustion.   
  
Clinical evidence demonstrating the utility of inorganic nitrate in cardiovascular health   
Kapil, V; Weitzberg E; Lundberg, J.; and Ahluwalia, A.  
Nitric Oxide 38:45-57. 2014.  
 
Purpose: Review discussed the evidence testing the utility of NO3- - NO2 – NO pathway for NO 
synthesis in CV health and disease. Methods: Both rat and human models were reviewed and 
discussed.  Findings: 2/3 of absorbed NO3- is excreted unchanged in the urine. Most of the 
remaining NO3- is concentrated from the circulation in the salivary glands of NO3- by a sialic acid 
transporter and then secreted into the oral cavity as NO3- rich saliva at 10x higher than plasma. 
This is known as the entero-salivary circulation. In rat aortic rings, application of low NO20 
(2.5 uM) whilst inactive under physiological conditions was shown to relax contracted rat aorta 
under acidci (6.6 pH). Cosby et al. Demonstrated that infusion of NaNO2 into the human forearm 
causes vasorelaxation with concomitant increased forearm blood flow – augmented during 
exercise. Webb et al. Used dietary supplementation in BRJ and found a reduction in BP over a 24 
hour period with peak reductions 2.5-3 h after ingestion coinciding with peak elevations in plasma 
NO2-. Another study found that lowered BP was sustained for 15 days compared to control with 
no evidence of tachyphylaxis. Females may have a decreased basal NO2- level due to decreased 
sensitivity due to possible “saturation” of the vasodilatory effect of NO2- proposed by Dejam et 
al. NO3- supplementation improves BF and blood vessel density. NO2- supplementation in pre-
clinical models with IR injury reduce infarct size and improve left ventricular function. Pre-
treatment up to 2 hours prior to delivery of IR injury with dietary nitrate prevented IR induced 
endothelial dysfunction. Inorganic nitrate reduced arterial stiffness as measured by PWV 3 hours 
after ingestion. NO generated by eNOS has been shown to induce mitochondrial biogenesis. Wylie 
7 
et al. Showed that non-respondent highly trained athletes turned into responders of NO3- by 
increasing the NO3- dose. Kenjale et al. Found that dietary NO3- extended peak walk time by 
almost 20% in patients with PAD an effect that could be related to improved mitochondrial 
efficiency or an increased BF to affected limbs. Inorganic nitrate has half life of 6 hours in human 
plasma whereas nitrate is 15-45 minutes.  Conclusion: Nitrate-nitrite-NO pathway can be 
manipulated to boost NO activity in vivo to benefit CVD, increase exercise capacity, and 
metabolism. This may be a cheap way to improve overall health in CVD patients as well as CV 
health for all.   
  
Effects of short-term dietary nitrate supplementation on blood pressure, O2 uptake kinetics, 
and muscle and cognitive function in order adults   
Kelly, J Fulford, J; Vanhatalo, A; Blackwell, J; French, O; Bailey, S; Gilchrist, M; Winyard, P ans 
Jones, AM 
American Journal of Applied Physiology R73-83. 2012.  
 
Purpose: Aims: Assess whether the physiological effects of dietary nitrate supplementation 
reported previously in young adults are also evident in older adults. And use H magnetic resonance 
spectroscopy (MRS) brain-scanning to determine whether NO3- can influence brain 
metabolites.  Methods: Double-blind, randomized, crossover study with 12 older adults (6 male 
and 6 female) aged 64+-4 for males and 63+-2 years for females.  BR supplementation was 140 
ml/day or NO3- depleted BR for 2.5 days prior to each subsequent lab visit. Walking exercise 
treadmill tests determine pulmonary VO2 and a 6-min walk test was used to determine functional 
capacity. There were also 3 cognitive tests involved to assess whether BR supplementation altered 
brain function with key metabolites. A single-leg knee extension exercise was also competed to 
assess muscle PCr levels. Findings: BR supplementation elevated plasma nitrite levels by 503% 
relative to control and then a 418% increase compared to placebo. BR significantly reduced 
systolic, diastolic, and MAP compared to both control and placebo trials. There was so significant 
difference in VO2 between placebo and BR during the baseline walking period. And steady state 
VO2 was unchanged between treatments. BR supplementation did decrease the O2 
deficit (15% decrease) and reduce the mean response time for VO2 compared to placebo. BR did 
not significantly alter functional capacity as measured by the 6 minute walk test which measured 
the total distance covered. Between the 3 cognitive tests assessed, there were no differences 
between any of the tests in terms of BR or placebo trials.  Conclusion: NO3- supplementation 
significantly reduced BP and the VO2 mean response time in healthy older adults. BR 
supplementation did not significantly reduce O2 cost of walking, functional walking performance, 
or the muscle metabolic response to low-intensity exercise or any brain metabolite concentrations 
or cognitive function. Short-term NO3- supplementation results in a 4x increase in plasma nitrite 
levels and significant reductions in resting BP in normotensive older adults. These can result in 
reducing the risk for hypertension and CVD in older adults. The VO2 kinetics were increased 
during treadmill walking although it did not translate to enhanced performance during the 6 MWT. 
This may result in therapeutic interventions for older adults with hypertension risk and may 
improve their VO2 kinetics.   
  
Dietary nitrate supplementation enhances muscle contractile efficiency during knee-extensor 
exercise in humans   
8 
Bailey SJ, Fulford J, Vanhatalo A, Winyard PG, Blackwell JR, DiMenna FJ, Wilkerson DP, 
Benjamin N, Jones AM. 
Journal of Applied Physiology 135-48. 2010.  
 
Purpose: Aim of the study was to determine why after NO3- supplementation there is a reduced 
O2 cost with submaximal exercise and an improved tolerance of high-intensity exercise. Study 
hypothesized that NO3- supplementation would reduce both low and high-intensity exercise O2 
cost and this would be accompanied by intramuscular PCr degradation. It was also hypothesized 
that exercise tolerance would be enhanced following BR supplementation due to a sparing effect 
of PCr. Methods: Study was a randomized, double-blind, crossover study design that included 7 
health male adults (28+-7) who were all recreationally active. Three MVC of quadriceps were 
completed along with an incremental test using two-legged knee-extensions to establish peak work 
rate. The load for the first step was 4 kg per leg and the load was increased by 1 kg for each 
subsequent increment until intolerance. Supplementation was 6 days of BR (5.1 mmol/day) given 
as 0.5 L per day or blackcurrant juice as the placebo. Subjects completed two 4 min bouts of low-
intensity exercise and one bout of high-intensity exercise with 6 mins of passive recovery 
separating each exercise bout.  Findings: BP and MAP was significantly reduced relative to 
PL. VO2 from rest to low-intensity exercise was reduced by 25% after BR supplementation. End-
exercise VO2 was also reduced following BR supplementation. Work efficiency was calculated 
by dividing exercise work rate by the difference between the exercise energy expenditure and the 
baseline energy expenditure. Work efficiency was significantly reduced after BR. VO2 slow 
component was significantly reduced (50%) after BR. NO3- supplementation also resulted in a 
36% reduction in the amplitude of PCr degradation during low-intensity exercise. Pi and [ADP] 
were reduced during BR trials. Mean ATP turnover rate from PCr hydrolysis over low-
intensity was lower following BR. [PCr] slow component amplitude was significantly reduced 
(59%) after BR. All 7 subjects were able to increase their time to task failure after BR. Conclusion: 
BR reduced O2 cost during exercise of both low and high-intensity exercises in young healthy 
males. This was done by reducing ATP cost of muscle force production. NO3- supplementation 
also improves the tolerance of high-intensity exercise as reflected by the reduction to which 
finite PCr levels were reserved over time. The reduced O2 cost appears to be manifested only 
during skeletal muscle contractions. VO2 required for same work rate was reduced during both 
low and high intensity exercises with BR. PCr concentrations were reduced with BR while pH 
remain unchanged. There was an improved tolerance to high intensity exercise.   
  
Cardiopulmonary Function and Age-related decline across the breast cancer survivorship 
continuum   
Jones LW, Courneya KS, Mackey JR, Muss HB, Pituskin EN, Scott JM, Hornsby WE, Coan AD, 
Herndon JE 2nd, Douglas PS, Haykowsky M.Journal of Clinical Oncology 2530-7. 2012.  
 
Purpose: To evaluate cardiopulmonary function across breast cancer continuum and its prognostic 
significance in women with metastatic disease. Methods: 248 women were divided into 4 cohorts 
of either before, during, or after (6 months – 3 years) adjuvant therapy or in the 4th cohort being a 
therapy group for metastatic breast cancer treatment. These results were compared to those of age 
and sex matched healthy controls. Subjects completed an incremental cycle ergometer test to 
measure VO2 peak. After a 3 min baseline, patients began cycling at 20 W and workloads increase 
5-20 W/min until volitional exhaustion. Hb was measured through CBC. Findings: Resting HR 
was significantly higher in the during adjuvant group. SBP was highest in the after adjuvant group 
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compared to the other groups. Hb was significantly lower in the during treatment group. VO2 peak 
averaged 17.8 +- 4.3 ml/kg/min which was equivalent to 27%-17% lower compared to the matched 
controls. 32% of the sample had a VO2 peak less than 15.4 ml/kg/min which is the minimal aerobic 
capacity required for functional independence. The overall mean VO2 response was 34% less than 
that of the healthy sedentary matched controls. Conclusion: Breast cancer patients have a 
significant impairment in cardiopulmonary function over the entire continuum of the disease. 1/3 
of the patients tested have a VO2 peak less than the functional independence threshold and they 
reached a predicted age-related VO2 peak 20-30 years on average earlier than health women 
without breast cancer history.   
  
Cardiovascular reserve and risk profile of postmenopausal women 
after chemoendocrine therapy for hormone receptor-positive operable breast cancer   
Jones LW, Haykowsky M, Pituskin EN, Jendzjowsky NG, Tomczak CR, Haennel RG, Mackey 
JR. 
The Oncologist 1156-64. 2007. 
  
Purpose: To examine CV function and risk profile of postmenopausal women treated 
with chemoendocrine therapy for hormone receptor-positive operable breast 
cancer. Specifically to explore potential differences between women receiving aromatase 
inhibitors vs. Tamoxifen. It was hypothesized that breast cancer patients would have worse CV 
function compared to age and sex matched controls.  Methods: 47 breast cancer patients (all 
received chemotherapy) and 11 health age and sex matched controls were studied. Each completed 
an incremental exercise test on a cycle ergometer (15W increase every 2 mins) to determine 
cardiopulmonary measurements. Blood pressure, HR, SV, Q, cardiac power output (Q x MAP) 
were obtained at the end of each exercise stage. Results: HR, MAP and SBP were significantly 
higher in cancer patients compared to controls. Peak exercise power output, absolute VO2 peak, 
VS, and Q were all significantly lower in patients compared to controls. Breast cancer patients 
with the greatest impairment in VO2 peak had the worst CVD risk profile. CVD risk factors were 
consistently more unfavorable in those being treated with aromatase inhibitors than 
tamoxifen. VO2 peak in patients was measured at 24% below that of controls. Conclusion: Breast 
cancer patients being treated with chemoendocrine therapy has a lower peak VO2 as well as worse 
CV measurements compared to matched health controls. Results indicate that impaired VO2 may 
be secondary to a lower stroke volume and Q at peak exercise, thus resulting in a concomitant 
reduction in O2 delivery to the active skeletal muscles. Impaired LV preload or contractility is 
likely responsible for low SV in breast cancer patients. Study was conducted 3 years (average) 
following chemotherapy cessation thus suggesting that LV function may not fully recover 
following completion of chemotherapy and/or radiotherapy. Thus, breast cancer patients have a 
significantly lower cardiorespiratory fitness level and lower cardiac functional reserve compared 
to their age and sex matched controls.   
  
Determinants of exercise intolerance in breast cancer patients prior to anthracycline 
chemotherapy   
Beaudry RI, Howden EJ, Foulkes S, Bigaran A, Claus P, Haykowsky MJ, Gerche A 
Physiological Reports 13971. 2019.  
 
Purpose: Authors hypothesized that impairment of peak VO2 in breast cancer patients prior to 
adjuvant chemotherapy (prior to anthracycline treatment) is attributable to decreased exercise 
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cardiac Q despite preserved RV and LV ejection fraction.  Methods: 29 breast cancer patients and 
10 health age and sex matched controls completed the study which included an incremental 
exercise test performed on an upright cycle ergometer with a 10-25 W power output initially and 
then increased 10-30 W/min until volitions exhaustion. Then subjects were placed on a cycle 
ergometer where they had intensities of 20, 40, and 60% of peak power output (obtained from 
incremental test) and each stage was maintained for 1-3 minutes. It was previously determined that 
66% of peak power during upright cycle corresponded to peak exercise in a supine position. 
Results: Peak exercise power output and VO2 were significantly lower (30% lower) in breast 
cancer patients compared to their healthy matched controls. RV and LV EDV index, ESV index, 
SV index, and cardiac index were all also lower in breast cancer patients vs 
controls. Conclusion: Submaximal and peak exercise RV and LV ejection fraction in breast cancer 
patients prior to adjuvant chemotherapy have significant exercise intolerance compared to their 
healthy age and sex matched controls. This is secondary their reduced RV and LV EDV.   
  
Peak Oxygen Consumption and long-term all-cause mortality in nonsmall cell lung cancer   
Jones LW, Watson D, Herndon JE, Eves ND, Haithcock BE, Loewen G, Kohman L. 
Cancer 4825-32. 2010.  
 
Purpose: To investiagte the prognostic significance of preoperative VO2 peak for long-term all-
cause mortality among operable candidates with nonsmall cell lung cancer (NSCLC). 
Methods: 398 patients (both men and women but 61% were males) were studied and their VO2 
peak was measured on a cycle ergometer. After 3 minutes of resting baseline data, patients began 
cycling at 20 W and workloads increased 5-20 W/min until volitional exhaustion. VO2 peak was 
categorized into 3 different groups with absolute values of: < 0.96 L/min, 0.96-1.29 L/min, and 
then >1.29 L/min. And then relatively into groups of: <13.9 ml/kg/min, 14-17.3 ml/kg/min, and 
then >17.4 ml/kg/min. Results: There was a 36% lower average compared to age and sex matched 
data from sedentary individuals. For the entire sample, the mortality rate decreased as VO2 peak 
was shown to increase in both absolute and relative terms. Median survival length for survival after 
participating in this exercise testing of each group is: group 1 - (low VO2 peak) was 13.3 months, 
group 2 – 16.1 months, and then group 3 - (highest VO2 peak) was 28 months. Conclusion: Data 
suggest a strong association between VO2 peak and all-cause mortality in patients with NSCLC 
as those who had a higher VO2 peak had a significant reduction in the risk of mortality by 
24%. Findings indicate that aerobic training may be a therapeutic implication for NSCLC patients 
to improve their clinical outcomes.   
  
Cardiovascular function and predictors of exercise capacity in patients with colorectal 
cancer   
Cramer L, Hildebrandt B, Kung T, Wichmann K, Springer J, Doehner W, Sandek A, Valentova 
M, Stojakovic T, Scharnagl H, Riess H, Anker SD, von Haehling S. 
Journal of the American College of Cardiology 1310-9. 2014.  
 
Purpose: To compare colorectal cancer (CRC) (both individuals who have received and have 
not received chemotherapy) to that of CHF in terms of the pathophysiology of both and then 
compare those two between that of healthy controls. It was hypothesized that knowing CHF 
pathophysiology we can better understand the impairment of exercise capacity in patients with 
CRC, independent of the commencement of chemotherapy. Methods: 50 CRC patients (26 being 
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treated with chemotherapy and then 24 not receiving chemotherapy) along with 51 CHF patients 
and 51 controls subjects performed a treadmill exercise test in order to obtain VO2 peak. DEXA, 
HRV via 24 hour electrocardiographic monitoring. Results: CRC patients had significantly higher 
resting HR and lower hemoglobin values compared with patients with CHF and 
controls. Compared with control subjects, LV ejection fraction was significantly reduced in CRC 
patients and in patients with CHF. LVESV index was increased for both CHF and CRC patients. 
LV mass was significantly increased in CHF compared with CRC and control groups. Thickened 
LV posterior wall was observed in CHF and CRC patients compared to health controls. CHF had 
significantly higher E:E’. CRC and CHF groups showed significant decreases in exercise 
performance (VO2 peak) and a significantly impaired breathing efficiency and anaerobic 
threshold. CRC patients who did not receive chemotherapy showed a significantly reduced peak 
VO2 peak and LV ejection fraction compared with control subjects. CRC patients had a 
significantly decreased lean mass value in their legs compared to the other two groups. CRC 
patients had significantly higher HR at rest compared to CHF and controls.Patients with CRC had 
a reduced exercise capacity compared with age matched controls. There were statistically 
significant reductions in LVEF as well as all markers of HRV. HRV was further decreased by the 
commencement of chemotherapy which was shown by lower peak HR and lower peak VO2 during 
exercise after chemotherapy initiation. Exercise capacity of CRC is severely impaired compared 
with controls and this effect is independent of chemotherapy. There were also decreases in 
sympathetic and parasympathetic function in CRC patients but high frequency was within normal 
range for those who did not receive chemotherapy. Thus suggestion that impairment of 
parasympathetic system occurs in early stages of chemotherapy. Chemotherapy patients had a 
decreased max HR during exercise compared to those without treatment. Conclusion: Exercise 
capacity in patients with CRC is significantly reduced. This held true for patients who did not 
undergo chemotherapy but worsened once chemotherapy was initiated.   
  
Cardiorespiratory and neuromuscular deconditioning in fatigued and non-fatigued breast 
cancer survivors   
Neil SE, Klika RJ, Garland SJ, McKenzie DC, Campbell KL. 
Supportive Care in Cancer 873-81. 2012.  
 
Purpose: Compare cardiorespiratory and neuromuscular deconditioning between breast cancer 
survivors who have cancer-related fatigue vs breast cancer survivors without cancer-related 
fatigue. It was hypothesized that the fatigued group would have a lower lactate threshold, lower 
VO2 peak, and greater decline in voluntary activation compared to the non-fatigued 
group. Methods: 16 breast cancer survivors with fatigue and 11 breast cancer survivors without 
fatigue were studied. Test day 1 consisted of the subjects undergoing a maximal incremental cycle 
ergometer test: 5 min warm up and then an increase of 20 W per stage (15 W for those less fit and 
25W/stage for those deemed more fit). Stages were 3 minutes long and part two of the test began 
once blood lactate increased > 1.0 mmol/L from baseline. Part 2 stages were reduced to 1 min 
durations. Test day 2 consisted of dynamometer with right leg knee flexion. Subjects performed 
3-s isometric MVC of quads and then a muscle fatiguing protocol of sustained isometric 
contractions at 30% MVC until volitional exhaustion. Results: Power at lactate threshold 
was significantly lower in the fatigued group. Absolute VO2 peak was also lower in the fatigued 
group compared to the non-fatigued. Non-fatigued group had a significantly lower voluntary 
activation (central fatigue) before and after sustained contraction than in the fatigue 
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group. Conclusion: Breast cancer survivors with persistent fatigue after treatment experience more 
cardiorespiratory deconditioning compared to non-fatigued breast cancer survivors.   
  
Inorganic nitrate is a possible source for systemic generation of nitric oxide   
Lundberg JO, Govoni M. 
Free Radical Biology and Medicine 395-400. 2004.  
 
Purpose: To study if ingested inorganic nitrate would result in increased plasma levels of nitrite 
and other related nitrogen oxides. Methods: 9 healthy subjects (5 male, 4 female) participated in 
the study in which they came to the lab in a fasted state and ingested 10 mg/kg of sodium nitrate 
in 100 ml of water. Blood was sampled prior to ingestion along with time points of 15, 30 60, and 
90 min after ingestion. Saliva was collected at those same time points and urine was collected prior 
to and then at 1, 2, and 3 hours after ingestion. Four subjects also participated in a sub-group test 
where they were not allowed to swallow during the first hour after nitrate ingestion. Results: At 
30 min after ingestion, salivary nitrate, nitrite, and S-nitrosothiols had all increased. Plasma nitrite 
increased at 15 min time point and continued to increase through the entire study 
duration. Conclusion: Plasma levels of nitrite increased for a sustained period of time after 
ingestion of nitrate and plasma S-nitrosothiols remained unchanged. The increase in plasma nitrite 
was abolished if the subject did not swallow thus indicating that saliva is a major source of plasma 
nitrite. Nitrite is a substrate for NO synthase-independent NO generation from nitrate. A reverse 
pathway for regeneration of NO from nitrate has been shown here.   
  
Dietary nitrate supplementation reduced the O2 cost of low-intensity exercise and enhances 
tolerance to high-intensity exercise in humans   
Bailey SJ, Winyard P, Vanhatalo A, Blackwell JR, Dimenna FJ, Wilkerson DP, Tarr J, Benjamin 
N, Jones AM. 
Journal of Applied Physiology 1144-55. 2009.  
 
Purpose: Authors hypothesized that BR supplementation would reduce the O2 cost of moderate-
intensity exercise and increase exercise tolerance during severe-intensity exercise as measured by 
the time to task failure for a cycle ergometer test. Methods: 8 healthy males were in the study that 
was a random, cross-over, placebo-controlled study with BRJ and blackcurrant juice with a 10 
day washout period. This was over the course of 6 day supplementation and with the ingestion of 
500 ml/day. Cycle ergometer test was 20 W baseline to moderate and severe-intensity work rates 
with subjects completing 2 moderate bouts of exercise of day 4 and then one moderate and one 
intense exercise on days 5 and 6. Results: BR ingestion significantly reduced SBP by 6 mmHg 
across the study time period. Deoxyhemoglobin concentration amplitude was reduced follow BR 
suggesting the fractional O2 extraction was reduced. A 19% reduction in the amplitude of 
pulmonary VO2 response vs placebo was observed for the same absolute moderate intensity 
cycling work rate. Absolute VO2 over final 30 seconds of moderate exercise was significantly 
lower after BR ingestion. Amplitude of VO2 slow component was significantly smaller following 
BR supplementation. Exercise tolerance was enhanced as shown by the increased time to task 
failure (16%). O2 cost was reduced by 20% of a given increment in work rate. VO2 response to 
severe exercise was increased by 7% and amplitude of subsequent VO2 slow component was 
reduced by 23%. Conclusion: 3-day of  BR supplementation (before testing but 6 total days of 
ingestion) significantly reduced SBP and the O2 cost of cycling for submaximal work rate and 
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increased the time to task failure during severe intensity exercise. VO2 was reduced by BR and it 
may be due in part to less O2 extraction was required consequent to a reduced aerobic energy 
turnover or muscle energy utilization. Since HR and VE were not significantly different between 
treatments, this suggests that reduction in VO2 originated in the skeletal muscles and not from 
alterations in the energetic cost of cardiorespiratory support processes. There was an improved O2 
efficiency which may be related to reduction in mitochondrial proton leak or proton pump 
slippage. O2 consumption reduction may also be due to reduced ATP cost of force 
production. NO3- supplementation may enhance exercise performance at high-intensities.   
  
Hypoxic modulation of exogenous nitrite-induced vasodilation in humans   
Maher AR, Milsom AB, Gunaruwan P, Abozguia K, Ahmed I, Weaver RA, Thomas P, Ashrafian 
H, Born GV, James PE, Frenneaux MP. 
Circulation 670-7. 2007.  
 
Purpose: Authors hypothesized that nitrites would have a greater dilator effect in capacitance than 
resistance vessels because of lower O2 tension and that resistance vessel diation should become 
more pronounced during hypoxemia. While subjects were breathing room air (group A) nitrite 
would be a potent dilator of capacitance vessels and when subjects were breathing 12% O2 (group 
B) nitrite would be a potent arteriolar dilator. Methods: 40 health subjects were recruited and split 
into two groups, group A (24 subjects) under normoxic conditions and then group B (14 subjects) 
under hypoxemic conditions. Forearm venous volume was measured along with FBFR which is a 
ratio of infused arm: control arm. BP cuffs were inflated over both upper arms at pressures of 0, 
10, 20, and 30 mmHg. In 7 subjects for group B 7.84 umol/min of nitrite was infused via 
intrabrachial. The other 7 subjects from group B were given 314 nmol/min. Results: Doses of 
nitrite at 784 nmol/min, 3.14 umol/min, and 7.84 umol/min showed large increases in forearm 
vascular  tone. Only 3.14 and 7.84 umol/min were noticeable increases in FBFR. At the peak dose, 
a 40% venodilation was observed. Conclusion: Hypoxia significantly enhanced the increase in 
FBFR during nitrite infusion. Hypoxia enhanced nitrite-induced relaxation in both vessel types 
compared with relaxation under normoxia however, veins had a greater proportional relaxation 
than arteries. Hypoxia is a prime determinant for the response to exogenous nitrite as both vessel 
types responded profoundly to hypoxic conditions. Significant augmentation in FBFR during 
hypoxia was seen with low-dose (314 nmol/min) nitrite which implies a physiological role under 
hypoxic conditions.   
  
Acute and chronic effects of dietary nitrate supplementation on blood pressure and the 
physiological responses to moderate-intensity and incremental exercise   
Vanhatalo A, Bailey SJ, Blackwell JR, DiMenna FJ, Pavey TG, Wilkerson DP, Benjamin N, 
Winyard PG, Jones AM. 
American Journal of Applied Physiology 1121-31. 2010.  
 
Purpose: It was hypothesized that 1) the plasma concentration would be elevated and BP reduced 
during one BR supplementation after 2.5 hours of ingestion (0.5 L) and then again after 5 and 15 
days of supplementation at 0.5 L/day. 2) the O2 cost of moderate-intensity exercise would be 
reduced 2.5 hours after the first dose of BR and then again 5 and 15 days after. 3) VO2 max and 
the GET would not be affected 2.5 hours after the first dose but would be increased after 5 and 15 
days of supplementation. Methods: 8 healthy subjects (3 female) were enrolled in the study. They 
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were physically active but not highly trained. They participated in the study which included cycling 
on a cycle ergometer with 3 min unloaded pedaling and then the work rate increased 30 W/min 
until volitional exhaustion. Subjects performed a two-step transition from 20 W baseline 
to moderate-intensity cycling at 90% GET with each bout lasting 5 minutes and bouts separated 
by 10 mins. After obtaining this data, subjects were randomly assigned to either a BRJ or 
PL group (blackcurrant juice) of 0.5 L/day and it was a crossover design with a 15 day 
supplementation period with 10-day washout period. Testing were on days 2, 5, 8, 12, and 15 to 
measure NO2- and BP and exercise testing were on days 5 and 15. Results: Nitrite concentration 
was elevated by 36% at 2.5 hours after ingestion and was highest on day 12 (59% increase) and 
day 15 (46% increase). SBP was significantly lowered after BR during all time points except day 
5. MAP was significantly lowered after BR all time points except day 8. VO2 at end exercise was 
significantly lowered after BR during all time points. Amplitude of VO2 response was 
significantly lower after BR compared to PL at all time points. Reduction of O2 cost (functional 
gain; increase in VO2 relative increase in external work) was significantly lower after BR from 
supplementation from baseline at all time points. A 5% reduction in steady state VO2 was 
observed during moderate intensity exercise. VO2 max had a significant increase at days 5 and 15 
after BR. Peak power output was significantly higher in first dose (2.5 hours) and after 15 days of 
BR. S1 slope of delta VO2/delta work rate was significantly reduced after 15 days of BR compared 
to baseline and 15 days PL. SBP was significantly reduced and was most pronounced after 12 days 
of supplementation. After 15 days of BRJ, peak power output and work rate associated with GET 
were higher than baseline and PL. Relative to baseline VO2 max was increased ~140 ml/min after 
15 days of nitrate supplementation. Conclusion: Lower O2 cost of moderate intensity exercise was 
shown after one dose of BRJ and then was maintained through a 15 day supplementation 
period. BR supplementation in young adults ~0.07 mmol/kg of nitrate resulted in a sustained 
reduction in SBP and DBP. The O2 cost of moderate-intensity exercise was significantly reduced 
after one dose of 0.5 L and these effects were maintained after 5 and 15 days of continued 
supplementation. Mechanisms that may contribute to increased VO2 max after 15-day BR include; 
1) NO-mediated changes in local perfusion to skeletal muscle and possible effects on Q. 2) Could 
be linked to increased mitochondrial mass as a consequence of elevated NO availability. 3) 
Chronic exposure of mammalian cells to NO result in cGMP mediated activation of regulatory 
protein sirtuin (SIRT1) which upregulated transcriptional factors and nuclear respiratory factors 
involved in coordination of mitochondrial fusion and fission events.   
  
Beetroot juice and exercise: pharmacodynamic and dose-response relationships   
Wylie LJ, Kelly J, Bailey SJ, Blackwell JR, Skiba PF, Winyard PG, Jeukendrup AE, Vanhatalo A, 
Jones AM. 
Journal of Applied Physiology 325-36. 2013.  
 
Purpose: Investigate the effects of acute NO3- doses of 4.2, 8.4, and 16.8 mmol of concentrated 
beet root juice consumed in either 70, 140, or 280 ml, respectively. Measurements being looked at 
were blood pressure over a 24 hour period and the effects on plasma nitrite. The physiological 
responses to step transitions to moderate-severe-intensity exercise, as well as determine the peak 
time response to each dose. Methods: Ten health, young males volunteered for the study which 
consisted of cycle ergometer exercise testing either on one of the three doses of BR or on a nitrate 
depleted placebo. All subjects were given a standardized breakfast and venous blood samples were 
taken 1, 2, 4, 8, 12, and 24 hours after ingestion of each beverage. Subjects were divided into two 
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groups with one being tested for pharmacodynamics of BR response and the other for dose 
response. Peak VO2 was determined from a ramp incremental test. During cycle ergometer tests, 
work rate was increased by 30 W/min until volitional exhaustion. Results: Peak elevation in plasma 
nitrite occurred 2 hours after ingestion of 8.4 mmol of nitrate. SBP was significantly lowered, 
compared to baseline, after all treatments with peak SBP decrease occurring 4 hours after post 
ingestion. This changes was correlated with the changes seen in plasma nitrite levels. Diastolic BP 
was also significantly reduced for 140 and 280 ml of BR consumption. These changes were also 
correlated with the changes seen in plasma nitrite levels. MAP was significantly decreased 
between all three doses of BR. There was a significant dose-dependent increase in plasma nitrate 
following BR after 2.5 hours. End exercise VO2 was significantly lowered after 280 ml of BR and 
there was a trend towards significant reduction for 140 ml of BR ingestion. VCO2 at baseline was 
increased significantly for all three BR doses. End exercise VCO2 was significantly higher for all 
three doses of BR. RER increased as the dose increased, this may be indicative of the sugars within 
the beverage of BR. VO2 and RER measured at task failure were not altered by dose or by 
treatment. BR doses of 140 and 280 ml showed an increase in time to task failure compared to 
their placebo counterparts. Conclusion: BR doses of 140 and 280 ml resulted in an increased time 
to task failure during severe intensity exercise. BR consumption may help maintain or improve 
vascular health in young adults as studies suggest that SBP lowering by 10 mmHg may reduce the 
risk of ischemic heart disease by 25% and the risk of stroke by 35%.  
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Chapter 2 - Introduction 
 
Advances in cancer therapy coupled with early detection strategies have contributed to the 
continual improvement in cancer specific mortality for many cancers including breast, 
lymphoma, prostate, and gastrointestinal cancers. However, in the years following anticancer 
therapy treatment, cancer survivors are at an increased risk of both cancer therapy and age-
related pathological outcomes; primary cardiovascular disease, exercise intolerance, and cancer-
related fatigue (Yeh, Tong et al. (2004). Unfortunately, there remains a paucity of 
pharmacological therapies that target these adverse outcomes (Shelburne, Adhikari et al. 2014).  
 
 
Exercise intolerance has consistently been reported in cancer survivors treated with neoplastic 
anticancer therapies. A recent cross-sectional cohort study of breast cancer patients, conducted 
by Jones et al. (2012), evaluated the effects of anticancer chemotherapy on cardiopulmonary 
exercise capacity before, during, and after chemotherapy administration (Jones, Courneya et al. 
2012). They reported that breast cancer patients had significant impairment of their 
cardiopulmonary exercise capacity, assessed via peak oxygen uptake (peak VO2), across the 
entire continuum of the disease with the most adverse impairments observed during 
chemotherapy administration and when the disease was metastatic. Additionally, this study 
reported that over 30% of these breast cancer patients had a peak aerobic exercise capacity that 
was below what is classified for functional independence (≤15.4 ml/kg/min). Furthermore, these 
pathological indices were also observed after the secession of anticancer therapy and into 
recovery. Additionally in a separate study, Jones et al. (2007) reported that breast cancer 
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survivors who have undergone anticancer therapy continue to have a significant reduction in 
their cardiopulmonary function into survivorship (Jones, Haykowsky et al. 2007). These 
impairments were seen in the cancer survivors who had the worst cardiovascular disease (CVD) 
risk profile, suggesting the more CVD risk factors a patient has, the stronger the association with 
cardiopulmonary function impairments. Furthermore, the investigators found that in addition to 
decreases in peak aerobic exercise capacity, breast cancer survivors treated with anticancer 
therapies have a significantly lower peak exercise stroke volume, cardiac output, and cardiac 
power output compared to their healthy age-matched controls. In agreement with this work, we 
have recently identified decreases in cardiac function in cancer survivors following anticancer 
therapy treatment (Manuscript: Lovoy et al. 2018) as well as decreases in microvascular function 
(Sutterfield, Caldwell et al. 2018). Furthermore, we have reported that cancer survivors have an 
impaired exercise blood flow and microvascular oxygenation response compared to non-treated 
controls, which, in addition to central limitations, may alter the balance between aerobic 
oxidative phosphorylation and anaerobic glycolysis within the contracting muscle. (Didier, 
Ederer et al. 2017). These vascular abnormalities, coupled with reductions in myocardial 
function, may therefore result in an integrative-dependent decrease in both convective and 
diffusive oxygen (O2) transport, predisposing to earlier exhaustion.   
 
Previous work has demonstrated that dietary nitrate (NO3
-) supplementation, through the 
ingestion of beet root juice (BR) or sodium nitrate, has positive effects on vascular regulation 
such as lowering blood pressure (Kapil, Weitzberg et al. 2014) as well as improving the 
oxidative capacity in young adults (Bailey, Winyard et al. 2009) (Bailey, Fulford et al. 2010) 
(Vanhatalo, Bailey et al. 2010) (Lansley, Winyard et al. 2011), older adults (Kelly, Fulford et al. 
2013), and in heart failure patients (Zamani, Rawat et al. 2015) (Eggebeen, Kim-Shapiro et al. 
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2016). Furthermore, NO3
- supplementation can increase exercise tolerance (Larsen, Weitzberg et 
al. 2010) (Bailey, Fulford et al. 2010). Thus, implementing a therapeutic intervention during or 
following anticancer therapy that includes NO3
- as treatment may allow cancer patients suffering 
from cardiopulmonary impairments to have an increased quality of life (Eggebeen, Kim-Shapiro 
et al. 2016). Additionally, we have recently demonstrated that 7-days of NO3
- supplementation 
improved diastolic function in cancer survivors through a significant increase in septal wall early 
diastolic velocity, strain rate during early diastolic filling, mitral valve late diastolic filling, and 
left ventricular longitudinal strain rate in early filling compared to placebo conditions 
(Manuscript: Lovoy et al. 2018). However, there remains a significant gap in knowledge for 
understanding the potential therapeutic use of NO3
- supplementation for improving parameters of 
exercise tolerance in cancer survivors with a history of anticancer therapy. Therefore, in this 
proof-of-concept trial, we hypothesized that administration of a single, acute-dose of NO3
-
supplementation will improve exercise capacity and exercise efficiency in cancer survivors.  
 
 
Chapter 3 - Methods 
 Participants 
All procedures were approved by the Kansas State University Institutional Review Board for 
research involving human subjects; and all standards conformed to the Declaration of Helsinki. 
Patients were eligible for inclusion in the study if they were at least 18 years of age, had a history 
of cancer, and received chemotherapy as part of their treatment. All patients must have been 
diagnosed as cancer-free at the time of the study. Patients were excluded from the study if they 
had any of the following: were diagnosed with overt cardiovascular disease, diabetes, kidney 
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diseases, high risk of kidney stones, hemochromatosis, or were a current smoker. Patients were 
instructed to take all regularly prescribed medications at their normally scheduled times. If 
patients were taking antioxidant supplements (e.g., fish oil) they were asked to refrain from 
taking these upon enrollment in the study and through the 7-day duration of the study. Patients 
were also asked to refrain from using antibacterial mouthwash and/or chewing gum on their 
exercise test days, as each have been shown to attenuate the reduction of NO3
- to nitrite (NO2
-), 
which is essential in the nitrate-nitrite-nitric oxide pathway within the entero-salivary pathway 
(Govoni, Jansson et al. 2008). The pathways of nitric oxide (NO) production including the 
reduction pathway of nitrate to nitrite to nitric oxide is depicted in Figure 1  (Jones, Thompson 
et al. 2018).  
  
 Experimental Procedures  
All patients had three separate visits to the laboratory with the first visit being a familiarization 
day. During the familiarization day, patients completed the informed consent, health history 
questionnaire, physical activity questionnaire, and a timeline sheet that outlined their cancer 
diagnosis and chemotherapy treatment history. Upon completion of paperwork, patients were 
then familiarized with the exercise protocol that was performed on a semi-recumbent cycle 
ergometer. The overall study consisted of a two-day randomized, double blind, placebo-
controlled crossover design, in which patients were assigned to either consume a nitrate-rich 
supplement in the form of a specifically formulated beetroot juice, or a nitrate-poor placebo in 
the form of blackcurrant juice. Patients then entered a 7-day washout period before entering the 
opposing arm of the study. Two-hours prior to each of the two testing sessions, patients orally 
consumed either 140 ml of concentrated nitrate-rich [NO3
-] beetroot juice supplement (BRJ; 
20 
BEET IT Sport, James White Drinks Ltd, Ipswich, UK) containing [12.2 mmol NO3
-], or 140 ml 
nitrate-depleted placebo supplement (PL; Blackcurrant juice with negligible NO3
- content). The 
BRJ dose of 140 ml [12.2 mmol NO3
-] was chosen for this experiment as it has previously been 
shown to be the most effective for lowering submaximal steady-state oxygen consumption and 
improving time to task failure in young, healthy adults when compared to dosages of 70 and 280 
ml (Wylie, Kelly et al. 2013). Additionally, the oral consumption of either treatment two-hours 
prior to exercise testing was chosen as previous work has demonstrated that peak plasma NO2
- 
levels have been observed 2-2.5 hours post-ingestion of BRJ (Wylie, Kelly et al. 2013). Patients 
were instructed to refrain from exercise at least 12 hours prior to testing as well as refraining 
from the consumption/usage of mouthwash, chewing gum, alcohol, or any type of food at least 
three hours prior to their scheduled laboratory visit time during their testing days. 
  
 Measurements 
 
 Plasma Nitrite and Complete Blood Count 
 
Upon arrival to the laboratory, trained phlebotomists drew blood samples from the patients into 
lithium heparin vacutainers (Becton Dickenson, NJ) for measurement of plasma NO2
- levels. 
Immediately following venous blood draws, the blood samples were centrifuged for 10 minutes 
at 3300 RPM, plasma was then collected and immediately frozen in a –80° C freezer for later 
NO2
- analysis. Measurements of [NO2-] were performed within 30 min after samples had thawed 
via chemiluminescence with an Ionic/Sievers NO analyzer (NOA 280i, GE, Boulder, CO) in 
triplicate after instrument calibration (Ferguson, Holdsworth et al. 2016). Additional venous 
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blood samples were drawn for a complete blood count (CBC) test to determine blood 
hemoglobin and hematocrit values. CBC tests were completed by Clinical Laboratory Scientists 
in Lafene Health Center at Kansas State University and results were collected once exercise 
testing was complete.  
 
 Cardiac and Arterial Blood Pressure Measurements 
 
Transthoracic echocardiography was performed at rest by an experienced sonographer, according 
to the standards of the American Society of Echocardiography using a commercially available 
system (Vivid S6 BT12; GE Healthcare) with a 1.5 to 4.3-mHz phased array transducer. Briefly, 
the left ventricular outflow tract (LVOT) diameter was obtained from the parasternal long axis 
and used to calculate LVOT cross-sectional area. Doppler velocity-time integral (VTI) of the 
LVOT was obtained from the apical 5-chamber view. Doppler VTI measures the distance blood 
travels during a period of flow. Measurements were performed over a 10 second period and used 
to calculate stroke volume (SV) and cardiac output (CO).  
 
𝑆𝑉 = 𝜋 × 
𝐿𝑉𝑂𝑇2
2
 × 𝐿𝑉𝑂𝑇 𝑉𝑇𝐼 
𝐶𝑂 =  
𝑆𝑉 × 𝐻𝑅
1000
  
  
 
Continuous beat-by-beat blood pressure measurements of systolic, diastolic, and mean arterial 
pressures were obtained by calibrated finger photoplethysmography (Finometer Pro; Finapress 
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Medical Systems, Amsterdam, The Netherlands). All blood pressure measurements were 
performed and monitored after the patients were positioned on the semi-recumbent cycle 
ergometer at rest and throughout both exercise tests. During exercise, cardiac output (Q) was 
calculated as heart rate (HR) × stroke volume (SV), with SV calculated using the ModelFlow 
method (Finometer Pro; Finapress Medical Systems) after correction for age, sex, body mass, 
and stature. These were corrected at rest using the echocardiography derived measurements of 
SV, which was time aligned to the arterial pressure recordings. Systemic vascular resistance 
(SVR) was calculated as the quotient of MAP and Q. The Finometer Pro has previously been 
validated to evaluate MAP, Q, and SVR responses in younger and older populations (Schutte, 
Huisman et al. 2004). Arterial oxygen saturation was measured via pulse oximeter on the finger 
(Datex Ohmeda S5 Light Monitor; GE Health Care, Milwaukee, WI).  
  
 Constant-Intensity Cardiopulmonary Exercise Test 
Upon completion of the echocardiographic examination, each patient performed a constant-
intensity cardiopulmonary exercise test on a hyperbolic Lode semi-recumbent cycle ergometer. 
Following a 2-min resting baseline, subjects pedaled at a self-selected range of 40–55 rpm for 6 
minutes at a constant workload of 30 Watts. Pedal rate along with leg length adjustment for the 
cycle ergometer were recorded and reproduced in subsequent tests in order to remain consistent 
with previous work (Wylie, Kelly et al. 2013). Breath-by-breath pulmonary ventilation and gas 
exchange data were continuously measured (Ultima CPX, Medical Graphics Corp., MN, USA). 
Steady-state oxygen uptake (VO2) was defined as the average VO2 during the final 60 seconds of 
exercise (Balady, Arena et al. 2010).  
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 Peak Cardiopulmonary Exercise Test 
Approximately 5 minutes after the constant-intensity cardiopulmonary exercise test, all patients 
performed a maximal exertion-limited incremental exercise test on the same semi-recumbent 
cycle ergometer using a ramp protocol. For five of the six patients, the ramp exercise protocol 
followed a computer programmed linear increase of 10 W/min as to maintain consistency with 
similar investigations (Eggebeen, Kim-Shapiro et al. 2016). One patient was an avid cyclist; 
thus, we altered the ramp increase to 15 W/min as recommended by American College of Sports 
Medicine (American College of Sports Medicine 2012). All ramp incremental tests were 
performed until volitional exhaustion. The exercise test was terminated if any of the American 
Heart Association absolute indications for test termination were met (Gibbons, Balady et al. 
1997). These included ST-segment elevation (1.0 mm) in leads without preexisting Q waves 
because of prior myocardial infarction, drop in systolic blood pressure > 10 mmHg; despite an 
increase in workload, when accompanied by any other evidence of ischemia, moderate-to-severe 
angina, central nervous system symptoms (ataxia, dizziness, near syncope), signs of poor 
perfusion (cyanosis or pallor), sustained ventricular tachycardia (VT) or other arrhythmia, 
including second or third-degree atrioventricular (AV) block; that interferes with normal 
maintenance of cardiac output during exercise, technical difficulties in monitoring the ECG or 
systolic blood pressure, the patient’s request to stop, if there was an exaggerated blood pressure 
response (systolic blood pressure >250 mmHg or diastolic blood pressure >115 mmHg), or if 
pedaling rate fell at least 10 rpm below the initial self-selected rate as followed by previous 
studies (Wylie, Kelly et al. 2013) (Eggebeen, Kim-Shapiro et al. 2016). Breath-by-breath 
pulmonary ventilation and gas exchange data were continuously measured, with peak VO2 
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determined as the average value during the final 30 seconds of exercise.  Maximal effort was 
confirmed by attainment of at least three criteria: (1) unable to maintain cadence; (2) a 
respiratory exchange ratio >1.1; (3) heart rate >90% of age-predicted maximum; (4) a plateau of 
V̇O2 defined as no expected increases (<150 ml min
-1) in V̇O2 from the previous test stage. 
 
 
Figure 1 - Schematic of pathways leading to the production of nitric oxide (NO) within the human 
body including the nitrate (NO3
-) – nitrite (NO2-) –nitric oxide (NO) reduction pathway.  (Jones, 
Thompson et al. 2018). 
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Figure 2 - Schematic illustration of exercise test protocol depicting both steady-state exercise 
followed by incremental exercise testing. 
  
 Statistical Analysis 
 
Data were analyzed with commercially available statistical software package (Sigmaplot; version 
12.5, Systat software, San Jose). All continuous variables are reported as mean ± SD unless 
otherwise stated. Study outcomes between the BR and PL measurements were compared by use 
of the paired t-test. Differences were considered statistically significant when p ≤ 0.05. Given the 
sample size and need to detect the smallest meaningful physiological differences, effect size 
comparisons were also made via Cohen’s d with threshold values for small, moderate, and large 
effects as 0.2, 0.5, >0.8 respectively.  
 
Chapter 4 - Results 
A total of sixteen cancer survivors were screened from previous study participant lists with eight 
initially interested in completing the resting echocardiograph and the cardiopulmonary exercise 
tests. Two patients were excluded from the peak cardiopulmonary test due to one having hip 
26 
surgery, and another patient having adverse health concerns consisting primarily of a history of 
atrial fibrillation. Thus, six patients completed all tests and were included in our final analyses.  
 
 Study Participants 
 
Six older adults (4 female and 2 male; n=4 breast cancer, n=2 lymphoma) who were cancer 
survivors with a history of anticancer therapy treatment completed the study. The mean age of 
the patients was 57 ± 11 years, height 169.5 ± 9.14 cm, weight 80.78 ± 27.23 kg as shown in 
Table 1. At the date of enrollment, all patients were diagnosed as cancer free for an average of 
4.83 ± 4.75 years, as indicated by the date of their last anticancer therapy treatment.  
 
Oral ingestion of NO3
- supplementation, through consumption of BRJ, significantly increased 
plasma nitrite levels (1300 ± 963 µM) compared to the nitrate-poor placebo supplementation 
(111 ± 49 µM; P = 0.02). This data suggests that there was successful reduction of NO3
- to NO2
-, 
which is consistent with both our previous findings (Manuscript: Lovoy et al 2018) and the 
reports of others (Wylie, Kelly et al. 2013) (Vanhatalo, Bailey et al. 2010) (Eggebeen, Kim-
Shapiro et al. 2016) (Kelly, Fulford et al. 2013) (Larsen, Weitzberg et al. 2010) (Larsen, 
Weitzberg et al. 2007) (Bescos, Rodriguez et al. 2011) (Kapil, Khambata et al. 2015) (Zamani, 
Rawat et al. 2015). 
 
 Constant Intensity Exercise Protocol 
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While under the BR condition, we observed significantly decreased relative (Figure 3) and 
absolute VO2 values during steady-state exercise compared to PL (Relative VO2: BRJ 8.46 ± 
2.24 vs. PL: 8.98 ± 2.40 ml/kg/min; p = 0.01; (Absolute VO2: BRJ 0.64 ± 0.10 vs. PL: 0.68 ± 
0.11 L/min; p = 0.01). No differences were observed for VCO2 during constant-intensity exercise 
during BRJ (0.60 ± 0.07 L/min) compared to PL conditions (0.61 ± 0.094 L/min; p = 0.36) or 
respiratory exchange ratio (RER) (BRJ: 0.94 ± 0.08 vs. PL: 0.90 ± 0.075; p = 0.12). 
Cardiovascular measurements during steady-state exercise were not different between conditions 
including, HR (BRJ: 87 ± 8 vs. PL: 88 ± 8 bpm; p = 0.33), cardiac output (BRJ: 7.7 ± 2.9 vs. PL: 
8.7 ± 4.1 L/min, p = 0.15), SV (BRJ: 87.4 ± 27.7 vs. PL: 96.3 ± 40.5 ml/beat; p = 0.18), systolic 
blood pressure (BRJ: 149 ± 10 vs. PL: 153 ± 13 mmHg; p = 0.23), diastolic blood pressure (BRJ: 
84 ± 9 vs. PL: 83 ± 9 mmHg; p = 0.44), left ventricular ejection time (BRJ: 329 ± 24 vs. PL: 333 
± 16 milliseconds; p = 0.26), or rate pressure product (BRJ 13049 ± 1659 vs. PL 13491 ± 1803  
beats/min mmHg; p = 0.21).  
  
 Peak Cardiopulmonary Exercise Test 
 
We did not find any significant difference between BRJ and PL conditions during the 
incremental exercise test for relative VO2 (BRJ: 22.4 ± 3.9 vs. PL: 23.1 ± 4.0 ml/kg/min; p = 
0.23) or absolute VO2 (BRJ: 1.77 ± 0.50 vs. PL: 1.86 ± 0.68 L/min; p = 0.20) (Figure 4A). This 
lack of difference between conditions held true for exercise time (BRJ: 14.8 ± 4.0 vs. PL: 14.9 ± 
4.3 minutes; p = 0.31), total work done (BRJ: 70.64 ± 29.5 vs. PL: 70.67 ± 30.71 kJ; p = 0.49) 
(Figure 4B) and gross exercise efficiency (BRJ: 5.23 ± 1.48 vs. PL: 4.97 ± 1.41 kJ/L O2; p = 
0.14) (Figure 4C). Similarly, we did not observe any differences between conditions for VCO2 
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(BRJ: 2.17 ± 0.57 vs. PL: 2.22 ± 0.77 L/min; p = 0.36), RER (BRJ: 1.23 ± 0.09 vs. PL: 1.22 ± 
0.12; p = 0.37), HR (BRJ: 135 ± 22 vs. PL: 139 ± 38 bpm; p = 0.36), or cardiac output (BRJ:12.3 
± 5.8 vs. PL: 14.2 ± 7.8 L/min; p = 0.18). It is noteworthy to state that our cardiopulmonary 
function exercise tests were assessed at peak VO2 as recommended for clinical populations as 
opposed to VO2 max tests (American Thoracic and American College of Chest 2003).  
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Table 1 - Patient characteristics. Values are average ± SD or number of patients (%); n = 5 for 
values. 
  
 
 
 
Table 1. Patient Characteristics 
Variable  
Age, mean (SD), y 57 (10.8) 
Male, n (%) 2 (33) 
Height, mean (SD), m 169.5 (9.1) 
Weight, mean (SD), kg 80.8 (27.2) 
Body mass index, mean 
(SD), kg/m2 
28.2 (9.9) 
Current smoker, n (%) 0 (0) 
Hypertension, n (%) 1 (20) 
Diabetes, n (%) 0 (0) 
Drug Therapy, n (%)  
    Β-Blocker 0 (0) 
    ACE inhibitor/ARB 1 (20) 
    Calcium channel blocker 0 (0) 
    Statin 0 (0) 
    Diuretic 0 (0) 
    Aspirin 0 (0) 
Cancer Type, n (%)  
    Breast 4 (67) 
    Lymphoma 2 (33)  
    Prostate 0 
Chemotherapy, n (%)  
    Alkylating Agent 6 (100) 
    Anthracycline 2 (33) 
    Antimicrotubule 5 (83) 
    Aromatase Inhibitor 0 
    Monoclonal Antibody 5 (83) 
Radiation, n (%) 3 (50) 
ACE indicates angiotensin-converting enzyme; 
ARB, angiotensin receptor blocker; 
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Table 2 - Pulmonary VO2 during constant intensity and incremental (peak) exercise intensity 
following dietary supplementation with either placebo (PL) or nitrate (BRJ; beetroot juice). 
Table 2. Effect of NO3- Versus Placebo 
 Effect of Placebo Effect of BRJ p Value 
Constant Intensity Cardiopulmonary Exercise Test 
VO2, ml∙kg-1∙min-1 8.98 (2.4) 8.46 (2.24) 0.01 
VO2, ml∙min-1 680 (113) 640 (99) 0.01 
VCO2, ml∙min-1 610 (94) 600 (70) 0.36 
Respiratory exchange ratio 0.90 (.07) 0.94 (0.08) 0.12 
Heart rate, beats∙min-1  
Cardiac output, L∙min-1        
88 (8) 
8.7 (4.1) 
86 (11) 
7.7 (2.9) 
0.15 
0.15 
Stroke volume, ml 96 (41) 87 (28) 0.18 
SBP, mmHg 153 (13) 149 (10) 0.23 
DBP, mmHg 83 (9) 84 (9) 0.44 
Left Ventricular Ejection Time, ms 333 (16) 329 (24) 0.26 
Rate pressure product, beats∙min-1∙mmHg 13491 (1803) 13049 (1659) 0.21 
Peak Cardiopulmonary Exercise Test 
Exercise time, min 14.9 (4.3) 14.8 (4) 0.31 
Total work done, kJ 70.67 (30.71) 70.64 (29.5) 0.49 
Total Exercise efficiency, kJ/L O2 4.97 (1.41) 5.23 (1.48) 0.14 
VO2, ml∙kg-1∙min-1 23.1 (4.0) 22.4 (3.9) 0.23 
VO2, ml∙min-1 1860 (683) 1770 (504) 0.20 
VCO2, ml∙min-1 2220 (769) 2170 (568) 0.36 
Respiratory exchange ratio 1.22 (0.12) 1.23 (0.09) 0.37 
Heart rate, beats∙min-1 140 (38) 135 (22) 0.36 
Cardiac output, L∙min-1        
Peak work rate, W 
14.3 (7.8) 
147.2 (39.1) 
12.3 (5.8) 
146 (36.1) 
0.18 
0.34 
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Figure 3 - Steady-state VO2 following either placebo or nitrate (NO3-) supplementation. 
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Figure 4 - (A) Peak VO2 following either placebo or nitrate (NO3-) supplementation.  
 (B) Total work done under either placebo or NO3- supplementation.  
 (C) Total efficiency under either placebo or NO3- supplementation. 
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Chapter 5 - Discussion  
The primary aim of this study was to investigate the therapeutic effects of inorganic dietary 
nitrate supplementation on the cardiorespiratory function of cancer survivors with a history of 
anticancer therapy. We have previously examined the effects of inorganic dietary nitrates on the 
cardiovascular system through a week long, randomized, double-blind, crossover study in which 
cancer survivors were supplemented with NO3
- for a one week duration. We found that compared 
to the nitrate-depleted placebo condition, cancer survivors who consumed nitrate-rich beetroot 
juice had a significantly improved left ventricular diastolic function (Manuscript: Lovoy et al. 
2018). However, we did not examine cardiopulmonary exercise capacity in this previous study. 
A critical finding of the present study was that during a single, acute-dose of NO3
- 
supplementation, through ingestion of 140 ml of beet-root juice (BRJ), there was a statistically 
significant decrease in relative and absolute VO2 during steady state exercise as reported in 
Table 2 and Figure 3. This is in line with our hypothesis as well as previous studies in healthy 
populations that have utilized NO3
- supplementation to observe changes in cardiopulmonary 
responses (Bailey, Fulford et al. 2010) (Wylie, Kelly et al. 2013) (Vanhatalo, Bailey et al. 2010).  
However, we did not observe any differences in the submaximal stroke volume or cardiac output 
for these cancer survivors. Furthermore, we did not observe any significant differences between 
BRJ and PL conditions for relative or absolute peak VO2 during the incremental ramp exercise 
test. Consistent with this finding, we did not observe differences in peak stroke volume, cardiac 
output, or arterial-venous oxygen difference between conditions. In total, these findings suggest 
that strategies that target NO bioavailability may provide a means of improving submaximal 
exercise economy in cancer survivors. The lack of a significant effect for cardiac function during 
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submaximal and peak exercise suggests that the mechanisms for this improved submaximal 
exercise efficiency is related to improved peripheral responses, not central cardiac performance.  
 
We found a significant decrease in steady-state VO2 after a single dose of NO3
-. This is 
consistent to what has been observed in younger, healthy subjects, but in contrast to those with 
heart failure. In agreement with our findings, Lansley et al. (2011) conducted a randomized, 
double-blind, crossover study in which young, healthy, physically active males were 
supplemented with 0.5 L/day of BRJ [6.2 mmol NO3
-] or 0.5 L/day of PL for 6 days. The 
investigators observed a 14% decrease in steady-state VO2 during a constant speed (4 km/hour) 
walking protocol while subjects were under the BRJ condition compared to PL (Lansley, 
Winyard et al. 2011). Additionally, previous work by Bailey et al. (2009) conducted a 
randomized, double-blind, crossover study with healthy, young, adult males. The subjects were 
also supplemented with either 0.5 L/day of BRJ [6.2 mmol NO3
-] or 0.5 L/day of PL. Exercise 
testing consisted of a step protocol from low-moderate (80% GET) and moderate-severe 
intensity exercise on a cycle ergometer. In accordance with our observations, the investigators 
reported a 19% reduction in the amplitude of the VO2 response from the step increment of 
moderate-severe cycling during the BR supplementation compared to PL. A significant reduction 
in absolute VO2 was also observed during the final 30 seconds of moderate intensity exercise 
following BRJ consumption compared to that of PL (Bailey, Winyard et al. 2009). Contrary to 
our findings as well as those previously presented by Lansley et al. and Bailey et al., work 
conducted with heart failure patients reported no difference in submaximal steady-state VO2 
between BRJ and PL conditions (Eggebeen, Kim-Shapiro et al. 2016). These findings were 
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reported for both acute (single dose of NO3
- through BRJ ingestion) and with one week of NO3
- 
supplementation.  
 
We believe that the significant reduction in O2 cost during steady-state exercise (Table 2 and 
Figure 3) was primarily due to an increase in peripheral responses, specifically oxidative 
phosphorylation efficiency. Mitochondrial oxidative phosphorylation efficiency is the amount of 
O2 consumed per ATP molecule produced (Hinkle 2005). Initially, NO3
- is reduced to NO2
- 
within the oral cavity where nitrate-reducing bacteria are found (Weitzberg and Lundberg 1998). 
From here, NO2
- is further reduced to bioactive nitric oxide (NO) within blood and tissues 
through several different pathways (Benjamin, O'Driscoll et al. 1994) (Modin, Bjorne et al. 
2001) (Millar, Stevens et al. 1998). One reduction pathway is a non-enzymatic reduction of 
inorganic nitrite to NO which is seen during acidic conditions where tissue pH is reduced to 
levels seen during hypoxic conditions and ischemia (Modin, Bjorne et al. 2001). Interstitial pH 
decreases during exercise and gradually continues to decline during graded exercise tests (Street, 
Bangsbo et al. 2001). This is suggestive that during exercise testing, interstitial pH would 
decrease in our patients thus causing an acidic environment which would allow plasma NO2
- to 
be further reduced to bioactive NO causing peripheral vasodilation. A crucial role for bioactive 
NO is modulating muscular contractions and increasing blood flow to working muscles (Stamler 
and Meissner 2001). This dilation allows an increase in blood flow resulting in more O2 carried 
to active muscles and the delivery of O2 from the blood to the active muscle is governed by 
mitochondrial O2 consumption (Korthuis 2011). This mechanism may explain why we observed 
a decrease in steady-state VO2 for cancer survivors.  
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From a molecular perspective, mammalian cytochrome c oxidase is the final enzyme in the 
mitochondrial electron transfer chain (Li, Park et al. 2006) which is part of the inner 
mitochondrial membrane in eukaryotes (Capaldi 1990). Cytochrome c oxidase has been regarded 
as a major regulation site for oxidative phosphorylation (Kadenbach, Huttemann et al. 2000). In 
the rat model, it has been shown that NO induces a kinetic constraint on cytochrome oxidase 
which decreases energy waste and increases oxidative phosphorylation efficiency (Clerc, 
Rigoulet et al. 2007). This mechanism works by NO binding to cytochrome c oxidase leading to 
partial mitochondrial respiration inhibition (Brown and Cooper 1994). These works suggest that 
NO is a physiological regulator of cytochrome oxidase and thus can cause inhibition of the 
enzyme which leads to an increase in oxidative phosphorylation.  
 
Mechanistically, we believe our results indicate that nitrate supplementation through a single, 
acute dose of beetroot juice, enhanced mitochondrial efficiency within the cancer survivor 
population. Reactive oxygen species (ROS) targets mitochondrial DNA that encodes several 
proteins essential for the function of the mitochondrial respiratory chain (Gogvadze, Orrenius et 
al. 2008). Additionally, most anticancer therapies elicit increases of ROS to damage cancer cells 
and consequently healthy tissue. This has been shown to induce mitochondrial DNA damage and 
impair mitochondrial function (Tocchetti, Cadeddu et al. 2019). This can lead to proton leakage 
in the electron transport chain which, in turn, leads to a reduction in the production of ATP. 
Work by Larsen et al. (2011) found that NO3
- supplementation [0.1 mmol/kg/day for 3 days] 
increased the respiratory control ratio, the ratio of respiration with amounts of ADP and 
respiration with amounts of substrates when ADP has been phosphorylated to ATP, compared to 
PL (NO3
- 8.5 ± 0.7 vs. PL 6.5 ± 0.7) (Larsen, Schiffer et al. 2011). Additionally, they found that 
Commented [A1]:  
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Commented [A3]: Starting new discussion.  
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there was an increased amount of ATP produced as well as a reduction in the amount of oxygen 
consumed under NO3
- supplementation compared to placebo. This lead to an increase in the P/O 
ratio, which is indicative of mitochondrial efficiency — further indicating that NO3- 
supplementation enhances oxidative phosphorylation efficiency and reduces VO2 during steady-
state exercise.  
 
In the present study, we saw no effect of NO3
- supplementation on submaximal cardiac function 
or arterial blood pressure. This is contrary to our previous work in cancer survivors treated with 
anticancer therapy in whom we observed a significant increase for resting parameters of left 
ventricular strain rate in early filling, early mitral septal wall annular velocity, and mitral A-wave 
velocity (Manuscript: Lovoy et al. 2018). Increases in these cardiovascular measurements are 
indicative of improved left ventricular diastolic function following BRJ supplementation 
compared to PL but do not appear to have translated to improved cardiac performance during 
exercise. However, the lack of difference in blood pressure between conditions is consistent with 
that seen in aforementioned work by Lansley et al. (2011) for young, healthy males (Lansley, 
Winyard et al. 2011). In contrast to our findings and those of Lansley et al., previous studies 
have reported a decrease in blood pressure after BRJ supplementation compared to PL for young, 
healthy (Bailey, Fulford et al. 2010) (Vanhatalo, Bailey et al. 2010) (Wylie, Kelly et al. 2013), 
older, healthy (Kelly, Fulford et al. 2013), and heart failure patients (Kapil, Khambata et al. 
2015) (Eggebeen, Kim-Shapiro et al. 2016). 
 
We did not observe a change in peak VO2 or total work performed during the peak 
cardiopulmonary exercise test following NO3
- supplementation. In contrast to our findings, the 
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aforementioned work by Lansley et al. (2011) reported a decrease in peak VO2 for young, 
healthy adults following a 6 day NO3
- supplementation period (Lansley, Winyard et al. 2011). 
However, despite the decrease in peak VO2, they observed an increased time to task failure 
(15%) under the BRJ condition compared to PL (Lansley, Winyard et al. 2011), highlighting an 
increased exercise efficiency with NO3
- supplementation. Additionally, it has been reported that 
heart failure patients show an enhanced peak VO2 when supplemented with BRJ compared to PL 
and they observed an increase in total amount of work done (Zamani, Rawat et al. 2015). The 
reason behind our lack of changes in peak VO2 or total work performed following BRJ 
supplementation is unknown, but several possibilities exist. First, we did not observe any 
changes in cardiac performance or the arterial-venous oxygen difference, which suggests our 
dose of NO3
- did not have any effect on our measured parameters of the O2 transport pathway. 
However, it should be noted that these parameters did not provide detailed insight into other 
aspects of convective and diffusive O2 transport (i.e. muscle blood flow or O2 diffusing 
capacity). Secondly, previous work has reported a significant age-related decline in 
cardiorespiratory fitness for both men and women with a classification VO2 value of 15.4 
ml/kg/min being reported for functional independence for older individuals aged 55-85 years 
(Paterson, Cunningham et al. 1999). Meaning that cardiorespiratory function exercise tests may 
not be a true representation for maximal effort for older individuals and thus lead to a lack in 
identifying the effects of BRJ. However, our group of cancer survivors were physically active 
and had a peak aerobic capacity above what is classified for functional independence. This 
observation may be partially explained by data collected from our health history and physical 
activity questionnaire reporting that all of our patients in this study were meeting the Physical 
Activity Guidelines for Americans of at least 150 minutes/week of moderate-intensity exercise 
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(US Department of Health and Human Services 2018). All patients engaged in structured 
moderate-intensity exercises an average of 3 days of the week and each exercise session lasting 
approximately one hour in duration. Additionally, our patients engaged in structured walking an 
average of 5 days of the week with each session lasting approximately one hour in duration. The 
majority of our patients (67%) also regularly engaged in strength training exercises each week. 
Being physically active and meeting the American physical activity guidelines is vital to overall 
health and quality of life. Huang et al. (1998) has reported that older individuals who are unfit 
are associated with more functional limitations however, this trend reverses for those who 
engage in physical activity (Huang, Macera et al. 1998). This suggests that older individuals who 
regularly engage in physical activity will have more functional independence and thus a better 
quality of life (Paterson, Cunningham et al. 1999). Lastly, we administered a single and uniform 
amount (140 ml) of NO3
- [12.2 mmol NO3
-]  which may not have been enough to elicit a 
cardiopulmonary response during peak exercise as indicated by the lack of difference in VO2 
responses between conditions. In contrast, Bescos et al. (2011) have reported a decrease in peak 
VO2 during a maximal exertion cycle ergometer test after an acute dose of NO3
- supplementation 
(Bescos, Rodriguez et al. 2011). However, these investigators administered NO3
- 
supplementation that was dose dependent on their subjects’ body mass at a ratio of 10 mg: 1 kg 
of body weight. In the present study, we administered a dose of 140 ml [12.2 mmol NO3
-] of BRJ 
to all patients regardless of body weight however, there was a range of 65 kg between our 
patients.  
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Limitations 
A major limitation to our study was the small sample size (n = 6) of cancer survivors. However, 
the cross-over study design allowed us to reduce variability within our measurements and 
allowed observation of differences between BRJ and PL conditions (Zamani, Rawat et al. 2015). 
Additionally, the patients that completed our study were relatively healthy with all patients 
regularly participating in physical activity. We believe this is partially explained by the length of 
time in which our patients were diagnosed as cancer free with the average time being 4 years and 
9 months and the longest time duration of 14 years. Thus, our sample may not accurately reflect 
that of the entire cancer survivor population, specifically those who have recently completed 
anticancer therapy treatment and are adjusting back to normal life activities while handling 
adverse side effects from their treatments.  
 
Conclusion 
In conclusion, a single, acute-dose of inorganic nitrate supplementation significantly reduced the 
oxygen consumption required during steady-state exercise for cancer survivors. Our findings 
suggest that NO3
- supplementation may be a beneficial therapeutic strategy for cancer survivors 
who have undergone chemotherapy as some of the side effects of chemotherapy have been 
shown to be irreversible and thus, have life-long lasting effects. Future studies are warranted to 
investigate the mechanisms that elicit a reduction in VO2 following longer term NO3
-  
supplementation specifically for clinical populations.  
 
 
 
41 
 
 
Chapter 6 - References  
 
American College of Sports Medicine (2012). Lifespan Effects of Aging 
and Deconditioning ACSM's Resource Manual for Guidelines for 
Exercise Testing and Prescription D. P. Swain, American College of 
Sports Medicine 91-134. 
American Thoracic, S. and P. American College of Chest (2003). 
"ATS/ACCP Statement on cardiopulmonary exercise testing." Am J 
Respir Crit Care Med 167(2): 211-277. 
Bailey, S. J., J. Fulford, A. Vanhatalo, P. G. Winyard, J. R. Blackwell, F. 
J. DiMenna, D. P. Wilkerson, N. Benjamin and A. M. Jones (2010). 
"Dietary nitrate supplementation enhances muscle contractile efficiency 
during knee-extensor exercise in humans." J Appl Physiol (1985) 
109(1): 135-148. 
Bailey, S. J., P. Winyard, A. Vanhatalo, J. R. Blackwell, F. J. Dimenna, 
D. P. Wilkerson, J. Tarr, N. Benjamin and A. M. Jones (2009). "Dietary 
nitrate supplementation reduces the O2 cost of low-intensity exercise 
and enhances tolerance to high-intensity exercise in humans." J Appl 
Physiol (1985) 107(4): 1144-1155. 
Balady, G. J., R. Arena, K. Sietsema, J. Myers, L. Coke, G. F. Fletcher, 
D. Forman, B. Franklin, M. Guazzi, M. Gulati, S. J. Keteyian, C. J. 
Lavie, R. Macko, D. Mancini, R. V. Milani, C. R. American Heart 
Association Exercise, C. Prevention Committee of the Council on 
Clinical, E. Council on, Prevention, D. Council on Peripheral Vascular, 
C. Interdisciplinary Council on Quality of and R. Outcomes (2010). 
"Clinician's Guide to cardiopulmonary exercise testing in adults: a 
scientific statement from the American Heart Association." Circulation 
122(2): 191-225. 
Benjamin, N., F. O'Driscoll, H. Dougall, C. Duncan, L. Smith, M. 
Golden and H. McKenzie (1994). "Stomach NO synthesis." Nature 
368(6471): 502. 
42 
Bescos, R., F. A. Rodriguez, X. Iglesias, M. D. Ferrer, E. Iborra and A. 
Pons (2011). "Acute administration of inorganic nitrate reduces 
VO(2peak) in endurance athletes." Med Sci Sports Exerc 43(10): 1979-
1986. 
Brown, G. C. and C. E. Cooper (1994). "Nanomolar concentrations of 
nitric oxide reversibly inhibit synaptosomal respiration by competing 
with oxygen at cytochrome oxidase." FEBS Lett 356(2-3): 295-298. 
Capaldi, R. A. (1990). "Structure and function of cytochrome c oxidase." 
Annu Rev Biochem 59: 569-596. 
Clerc, P., M. Rigoulet, X. Leverve and E. Fontaine (2007). "Nitric oxide 
increases oxidative phosphorylation efficiency." J Bioenerg Biomembr 
39(2): 158-166. 
Didier, K. D., A. K. Ederer, L. K. Reiter, M. Brown, R. Hardy, J. 
Caldwell, C. Black, M. G. Bemben and C. J. Ade (2017). "Altered Blood 
Flow Response to Small Muscle Mass Exercise in Cancer Survivors 
Treated With Adjuvant Therapy." J Am Heart Assoc 6(2). 
Eggebeen, J., D. B. Kim-Shapiro, M. Haykowsky, T. M. Morgan, S. 
Basu, P. Brubaker, J. Rejeski and D. W. Kitzman (2016). "One Week of 
Daily Dosing With Beetroot Juice Improves Submaximal Endurance and 
Blood Pressure in Older Patients With Heart Failure and Preserved 
Ejection Fraction." JACC Heart Fail 4(6): 428-437. 
Ferguson, S. K., C. T. Holdsworth, T. D. Colburn, J. L. Wright, J. C. 
Craig, A. Fees, A. M. Jones, J. D. Allen, T. I. Musch and D. C. Poole 
(2016). "Dietary nitrate supplementation: impact on skeletal muscle 
vascular control in exercising rats with chronic heart failure." J Appl 
Physiol (1985) 121(3): 661-669. 
Gibbons, R. J., G. J. Balady, J. W. Beasley, J. T. Bricker, W. F. 
Duvernoy, V. F. Froelicher, D. B. Mark, T. H. Marwick, B. D. 
McCallister, P. D. Thompson, Jr., W. L. Winters, F. G. Yanowitz, J. L. 
Ritchie, R. J. Gibbons, M. D. Cheitlin, K. A. Eagle, T. J. Gardner, A. 
Garson, Jr., R. P. Lewis, R. A. O'Rourke and T. J. Ryan (1997). 
"ACC/AHA Guidelines for Exercise Testing. A report of the American 
College of Cardiology/American Heart Association Task Force on 
Practice Guidelines (Committee on Exercise Testing)." J Am Coll 
Cardiol 30(1): 260-311. 
43 
Gogvadze, V., S. Orrenius and B. Zhivotovsky (2008). "Mitochondria in 
cancer cells: what is so special about them?" Trends Cell Biol 18(4): 
165-173. 
Govoni, M., E. A. Jansson, E. Weitzberg and J. O. Lundberg (2008). 
"The increase in plasma nitrite after a dietary nitrate load is markedly 
attenuated by an antibacterial mouthwash." Nitric Oxide 19(4): 333-337. 
Hinkle, P. C. (2005). "P/O ratios of mitochondrial oxidative 
phosphorylation." Biochim Biophys Acta 1706(1-2): 1-11. 
Huang, Y., C. A. Macera, S. N. Blair, P. A. Brill, H. W. Kohl, 3rd and J. 
J. Kronenfeld (1998). "Physical fitness, physical activity, and functional 
limitation in adults aged 40 and older." Med Sci Sports Exerc 30(9): 
1430-1435. 
Jones, A. M., C. Thompson, L. J. Wylie and A. Vanhatalo (2018). 
"Dietary Nitrate and Physical Performance." Annu Rev Nutr 38: 303-
328. 
Jones, L. W., K. S. Courneya, J. R. Mackey, H. B. Muss, E. N. Pituskin, 
J. M. Scott, W. E. Hornsby, A. D. Coan, J. E. Herndon, 2nd, P. S. 
Douglas and M. Haykowsky (2012). "Cardiopulmonary function and 
age-related decline across the breast cancer survivorship continuum." J 
Clin Oncol 30(20): 2530-2537. 
Jones, L. W., M. Haykowsky, E. N. Pituskin, N. G. Jendzjowsky, C. R. 
Tomczak, R. G. Haennel and J. R. Mackey (2007). "Cardiovascular 
reserve and risk profile of postmenopausal women after chemoendocrine 
therapy for hormone receptor--positive operable breast cancer." 
Oncologist 12(10): 1156-1164. 
Kadenbach, B., M. Huttemann, S. Arnold, I. Lee and E. Bender (2000). 
"Mitochondrial energy metabolism is regulated via nuclear-coded 
subunits of cytochrome c oxidase." Free Radic Biol Med 29(3-4): 211-
221. 
Kapil, V., R. S. Khambata, A. Robertson, M. J. Caulfield and A. 
Ahluwalia (2015). "Dietary nitrate provides sustained blood pressure 
lowering in hypertensive patients: a randomized, phase 2, double-blind, 
placebo-controlled study." Hypertension 65(2): 320-327. 
44 
Kapil, V., E. Weitzberg, J. O. Lundberg and A. Ahluwalia (2014). 
"Clinical evidence demonstrating the utility of inorganic nitrate in 
cardiovascular health." Nitric Oxide 38: 45-57. 
Kelly, J., J. Fulford, A. Vanhatalo, J. R. Blackwell, O. French, S. J. 
Bailey, M. Gilchrist, P. G. Winyard and A. M. Jones (2013). "Effects of 
short-term dietary nitrate supplementation on blood pressure, O2 uptake 
kinetics, and muscle and cognitive function in older adults." Am J 
Physiol Regul Integr Comp Physiol 304(2): R73-83. 
Korthuis, R. J. (2011). Skeletal Muscle Circulation Skeletal Muscle 
Circulation Morgan & Claypool Life Sciences  
Lansley, K. E., P. G. Winyard, J. Fulford, A. Vanhatalo, S. J. Bailey, J. 
R. Blackwell, F. J. DiMenna, M. Gilchrist, N. Benjamin and A. M. Jones 
(2011). "Dietary nitrate supplementation reduces the O2 cost of walking 
and running: a placebo-controlled study." J Appl Physiol (1985) 110(3): 
591-600. 
Larsen, F. J., T. A. Schiffer, S. Borniquel, K. Sahlin, B. Ekblom, J. O. 
Lundberg and E. Weitzberg (2011). "Dietary inorganic nitrate improves 
mitochondrial efficiency in humans." Cell Metab 13(2): 149-159. 
Larsen, F. J., E. Weitzberg, J. O. Lundberg and B. Ekblom (2007). 
"Effects of dietary nitrate on oxygen cost during exercise." Acta Physiol 
(Oxf) 191(1): 59-66. 
Larsen, F. J., E. Weitzberg, J. O. Lundberg and B. Ekblom (2010). 
"Dietary nitrate reduces maximal oxygen consumption while 
maintaining work performance in maximal exercise." Free Radic Biol 
Med 48(2): 342-347. 
Li, Y., J. S. Park, J. H. Deng and Y. Bai (2006). "Cytochrome c oxidase 
subunit IV is essential for assembly and respiratory function of the 
enzyme complex." J Bioenerg Biomembr 38(5-6): 283-291. 
Millar, T. M., C. R. Stevens, N. Benjamin, R. Eisenthal, R. Harrison and 
D. R. Blake (1998). "Xanthine oxidoreductase catalyses the reduction of 
nitrates and nitrite to nitric oxide under hypoxic conditions." FEBS Lett 
427(2): 225-228. 
Modin, A., H. Bjorne, M. Herulf, K. Alving, E. Weitzberg and J. O. 
Lundberg (2001). "Nitrite-derived nitric oxide: a possible mediator of 
'acidic-metabolic' vasodilation." Acta Physiol Scand 171(1): 9-16. 
45 
Paterson, D. H., D. A. Cunningham, J. J. Koval and C. M. St Croix 
(1999). "Aerobic fitness in a population of independently living men and 
women aged 55-86 years." Med Sci Sports Exerc 31(12): 1813-1820. 
Schutte, A. E., H. W. Huisman, J. M. van Rooyen, N. T. Malan and R. 
Schutte (2004). "Validation of the Finometer device for measurement of 
blood pressure in black women." J Hum Hypertens 18(2): 79-84. 
Shelburne, N., B. Adhikari, J. Brell, M. Davis, P. Desvigne-Nickens, A. 
Freedman, L. Minasian, T. Force and S. C. Remick (2014). "Cancer 
treatment-related cardiotoxicity: current state of knowledge and future 
research priorities." J Natl Cancer Inst 106(9). 
Stamler, J. S. and G. Meissner (2001). "Physiology of nitric oxide in 
skeletal muscle." Physiol Rev 81(1): 209-237. 
Street, D., J. Bangsbo and C. Juel (2001). "Interstitial pH in human 
skeletal muscle during and after dynamic graded exercise." J Physiol 
537(Pt 3): 993-998. 
Sutterfield, S. L., J. T. Caldwell, H. K. Post, G. M. Lovoy, H. R. 
Banister and C. J. Ade (2018). "Lower cutaneous microvascular 
reactivity in adult cancer patients receiving chemotherapy." J Appl 
Physiol (1985) 125(4): 1141-1149. 
Tocchetti, C. G., C. Cadeddu, D. Di Lisi, S. Femmino, R. Madonna, D. 
Mele, I. Monte, G. Novo, C. Penna, A. Pepe, P. Spallarossa, G. 
Varricchi, C. Zito, P. Pagliaro and G. Mercuro (2019). "From Molecular 
Mechanisms to Clinical Management of Antineoplastic Drug-Induced 
Cardiovascular Toxicity: A Translational Overview." Antioxid Redox 
Signal 30(18): 2110-2153. 
US Department of Health and Human Services. (2018). "Physical 
Activity Guidelines for Americans."  2nd  
Vanhatalo, A., S. J. Bailey, J. R. Blackwell, F. J. DiMenna, T. G. Pavey, 
D. P. Wilkerson, N. Benjamin, P. G. Winyard and A. M. Jones (2010). 
"Acute and chronic effects of dietary nitrate supplementation on blood 
pressure and the physiological responses to moderate-intensity and 
incremental exercise." Am J Physiol Regul Integr Comp Physiol 299(4): 
R1121-1131. 
Weitzberg, E. and J. O. Lundberg (1998). "Nonenzymatic nitric oxide 
production in humans." Nitric Oxide 2(1): 1-7. 
46 
Wylie, L. J., J. Kelly, S. J. Bailey, J. R. Blackwell, P. F. Skiba, P. G. 
Winyard, A. E. Jeukendrup, A. Vanhatalo and A. M. Jones (2013). 
"Beetroot juice and exercise: pharmacodynamic and dose-response 
relationships." J Appl Physiol (1985) 115(3): 325-336. 
Yeh, E. T., A. T. Tong, D. J. Lenihan, S. W. Yusuf, J. Swafford, C. 
Champion, J. B. Durand, H. Gibbs, A. A. Zafarmand and M. S. Ewer 
(2004). "Cardiovascular complications of cancer therapy: diagnosis, 
pathogenesis, and management." Circulation 109(25): 3122-3131. 
Zamani, P., D. Rawat, P. Shiva-Kumar, S. Geraci, R. Bhuva, P. Konda, 
P. T. Doulias, H. Ischiropoulos, R. R. Townsend, K. B. Margulies, T. P. 
Cappola, D. C. Poole and J. A. Chirinos (2015). "Effect of inorganic 
nitrate on exercise capacity in heart failure with preserved ejection 
fraction." Circulation 131(4): 371-380; discussion 380. 
 
